{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:24:19Z","timestamp":1793316259465,"version":"4.5.0"},"reference-count":471,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204864"],"award-info":[{"award-number":["82204864"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This review introduces a paradigm-shifting concept of Dual Distinct Immunotherapy (DDI), which strategically integrates two distinct immunotherapeutic modalities to overcome the limitations of current monotherapies and dual immune checkpoint inhibitor (ICI) combinations. The concept of DDI extends beyond traditional ICI combinations to encompass various innovative pairings: ICIs with oncolytic viruses (OVs), adoptive cell therapies (CAR-T\/TIL), cancer vaccines, or cytokine therapies. These combinations demonstrate unique synergistic mechanisms and enhanced therapeutic potential through multi-faceted immune activation. Significantly, this work advances the field by analyzing potential third-agent sensitizers to complement DDI strategies. We systematically evaluate emerging candidates including PCNA inhibitors, HDAC inhibitors, and carbonic anhydrase inhibitors, focusing on their ability to modulate the tumor microenvironment and enhance immunotherapy responses. This \"DDI\u2009+\u20091\" approach targets alternative pathways to overcome resistance mechanisms and expand treatment efficacy to traditionally immunotherapy-resistant cancers. Through comprehensive analysis of preclinical evidence and ongoing clinical trials, we address critical challenges in immunotherapy, including primary and acquired resistance, cold tumor conversion, and pathway exhaustion. The review synthesizes current findings while proposing innovative solutions and future research directions. Our framework demonstrates how strategic integration of multiple immune-based approaches can significantly improve therapeutic outcomes across diverse cancer types, potentially revolutionizing cancer treatment paradigms. This concept of DDI, enhanced by rational third-agent selection, represents a promising direction for addressing urgent clinical needs in oncology. By establishing a theoretical foundation for this approach, we aim to guide future research and clinical applications in cancer immunotherapy.<\/jats:p>","DOI":"10.1186\/s40164-025-00705-9","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T17:29:10Z","timestamp":1759166950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer"],"prefix":"10.1186","volume":"14","author":[{"given":"Yuqian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"705_CR1","first-page":"451","volume":"10","author":"B Chhikara","year":"2022","unstructured":"Chhikara B, Parang K. Global cancer statistics 2022: the trends projection analysis. Chem Biol Lett. 2022;10:451.","journal-title":"Chem Biol Lett"},{"key":"705_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092639","author":"WS Shin","year":"2023","unstructured":"Shin WS, Xie F, Chen B, Yu P, Yu J, To KF, et al. Updated epidemiology of Gastric cancer in Asia: decreased incidence but still a big challenge. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15092639.","journal-title":"Cancers (Basel)"},{"key":"705_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10112125","author":"D Horgan","year":"2022","unstructured":"Horgan D, Mia R, Erhabor T, Hamdi Y, Dandara C, Lal JA, et al. Fighting cancer around the world: a framework for action. Healthcare. 2022. https:\/\/doi.org\/10.3390\/healthcare10112125.","journal-title":"Healthcare"},{"key":"705_CR4","first-page":"1","volume":"1","author":"A Valavanidis","year":"2022","unstructured":"Valavanidis A. Half of the World\u2019s Cancer Deaths are Preventable. Reductions of lifestyle-modifiable risk factors: smoking, obesity-unhealthy diet, and drinking excess alcohol Introduction. 2022;1:1\u201326.","journal-title":"Reductions of lifestyle-modifiable risk factors: smoking, obesity-unhealthy diet, and drinking excess alcohol Introduction"},{"issue":"23","key":"705_CR5","doi-asserted-by":"publisher","first-page":"5983","DOI":"10.3390\/cancers14235983","volume":"14","author":"Q Chen","year":"2022","unstructured":"Chen Q, Lu L, Ma W. Efficacy, safety, and challenges of CAR T-cells in the treatment of solid tumors. Cancers. 2022;14(23):5983.","journal-title":"Cancers"},{"issue":"8","key":"705_CR6","doi-asserted-by":"publisher","first-page":"12567","DOI":"10.1021\/acsnano.1c02103","volume":"15","author":"S Gao","year":"2021","unstructured":"Gao S, Yang X, Xu J, Qiu N, Zhai G. Nanotechnology for boosting cancer immunotherapy and remodeling tumor microenvironment: the horizons in cancer treatment. ACS Nano. 2021;15(8):12567\u2013603.","journal-title":"ACS Nano"},{"key":"705_CR7","volume-title":"Cancer nanomedicine: special focus on cancer immunotherapy","author":"S Tavakolpour","year":"2021","unstructured":"Tavakolpour S, Karami F. Cancer nanomedicine: special focus on cancer immunotherapy. Cham: Springer International Publishing; 2021."},{"issue":"1","key":"705_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41582-019-0268-z","volume":"16","author":"JD L\u00fcnemann","year":"2020","unstructured":"L\u00fcnemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H. Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nat Rev Neurol. 2020;16(1):56\u201362.","journal-title":"Nat Rev Neurol"},{"key":"705_CR9","first-page":"5","volume":"4","author":"T Xu","year":"2021","unstructured":"Xu T. Cancer immunotherapy: emerging topics and future perspectives. Landscape. 2021;4:5.","journal-title":"Landscape"},{"issue":"6","key":"705_CR10","doi-asserted-by":"publisher","first-page":"6788","DOI":"10.1002\/cam4.5468","volume":"12","author":"LJ Brown","year":"2023","unstructured":"Brown LJ, da Silva IP, Moujaber T, Gao B, Hui R, Gurney H, et al. Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres. Cancer Med. 2023;12(6):6788\u2013801.","journal-title":"Cancer Med"},{"issue":"1","key":"705_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40164-023-00372-8","volume":"12","author":"W Ma","year":"2023","unstructured":"Ma W, Xue R, Zhu Z, Farrukh H, Song W, Li T, et al. Increasing cure rates of solid tumors by immune checkpoint inhibitors. Exp Hematol Oncol. 2023;12(1):10.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"705_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s40164-024-00583-7","volume":"13","author":"P Yao","year":"2024","unstructured":"Yao P, Liu YG, Huang G, Hao L, Wang R. The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances. Exp Hematol Oncol. 2024;13(1):118.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"705_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","volume":"13","author":"J Li","year":"2024","unstructured":"Li J, Chen P, Ma W. The next frontier in immunotherapy: potential and challenges of CAR-macrophages. Exp Hematol Oncol. 2024;13(1):76.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"705_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40164-022-00291-0","volume":"11","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Liu Z, Wei W, Li Y. TCR engineered T cells for solid tumor immunotherapy. Exp Hematol Oncol. 2022;11(1):38.","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"705_CR15","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","volume":"11","author":"M Aldea","year":"2021","unstructured":"Aldea M, Andre F, Marabelle A, Dogan S, Barlesi F, Soria J-C. Overcoming resistance to tumor-targeted and immune-targeted therapies. Cancer Discov. 2021;11(4):874\u201399.","journal-title":"Cancer Discov"},{"issue":"1","key":"705_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01164-5","volume":"14","author":"S Zhu","year":"2021","unstructured":"Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14(1):156.","journal-title":"J Hematol Oncol"},{"issue":"21","key":"705_CR17","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309\u201337.","journal-title":"Cell"},{"issue":"1","key":"705_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20(1):25\u201339.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"705_CR19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"705_CR20","doi-asserted-by":"publisher","first-page":"834","DOI":"10.4103\/jcrt.JCRT_1241_20","volume":"17","author":"R Dhar","year":"2021","unstructured":"Dhar R, Seethy A, Singh S, Pethusamy K, Srivastava T, Talukdar J, et al. Cancer immunotherapy: recent advances and challenges. J Cancer Res Ther. 2021;17(4):834\u201344.","journal-title":"J Cancer Res Ther"},{"issue":"2","key":"705_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","volume":"72","author":"A-L Cheng","year":"2020","unstructured":"Cheng A-L, Hsu C, Chan SL, Choo S-P, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72(2):307\u201319.","journal-title":"J Hepatol"},{"key":"705_CR22","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S358082","author":"Y Fan","year":"2022","unstructured":"Fan Y, Xue H, Zheng H. Systemic therapy for hepatocellular carcinoma: current updates and outlook. J Hepatocell Carcinoma. 2022. https:\/\/doi.org\/10.2147\/JHC.S358082.","journal-title":"J Hepatocell Carcinoma"},{"key":"705_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-021-02407-8","volume":"22","author":"S Vafaei","year":"2022","unstructured":"Vafaei S, Zekiy AO, Khanamir RA, Zaman BA, Ghayourvahdat A, Azimizonuzi H, et al. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell Int. 2022;22:1\u201327.","journal-title":"Cancer Cell Int"},{"key":"705_CR24","volume-title":"Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW","author":"PR Galle","year":"2024","unstructured":"Galle PR, Decaens T, Kudo M, Qin S, Fonseca L, Sangro B, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. American Society of Clinical Oncology; 2024."},{"issue":"5","key":"705_CR25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.hbpd.2022.08.003","volume":"21","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Qin L-X. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2022;21(5):420\u20139.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"705_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","volume":"62","author":"KM Hargadon","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29\u201339.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"705_CR27","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd3216","volume":"9","author":"S Kummar","year":"2010","unstructured":"Kummar S, Chen HX, Wright J, Holbeck S, Millin MD, Tomaszewski J, et al. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discovery. 2010;9(11):843\u201356.","journal-title":"Nat Rev Drug Discovery"},{"issue":"10","key":"705_CR28","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","volume":"5","author":"SL Topalian","year":"2019","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non\u2013small cell lung cancer treated with nivolumab. JAMA Oncol. 2019;5(10):1411\u201320.","journal-title":"JAMA Oncol"},{"key":"705_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bspc.2022.103575","volume":"75","author":"X Wu","year":"2022","unstructured":"Wu X, Hou Y, Zhang K. Switched system optimal control approach for drug administration in cancer chemotherapy. Biomed Signal Process Control. 2022;75:103575.","journal-title":"Biomed Signal Process Control"},{"issue":"4","key":"705_CR30","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2023","unstructured":"Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023;10(4):1367\u2013401.","journal-title":"Genes Dis"},{"issue":"1","key":"705_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16(1):223\u201349.","journal-title":"Annu Rev Pathol"},{"key":"705_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:1\u201314.","journal-title":"Mol Cancer"},{"key":"705_CR33","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","volume":"40","author":"MZ Wojtukiewicz","year":"2021","unstructured":"Wojtukiewicz MZ, Rek MM, Karpowicz K, G\u00f3rska M, Polity\u0144ska B, Wojtukiewicz AM, et al. Inhibitors of immune checkpoints\u2014PD-1, PD-L1, CTLA-4\u2014new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev. 2021;40:949\u201382.","journal-title":"Cancer Metastasis Rev"},{"key":"705_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108469","volume":"104","author":"B-J Chen","year":"2022","unstructured":"Chen B-J, Zhao J-W, Zhang D-H, Zheng A-H, Wu G-Q. Immunotherapy of Cancer by Targeting Regulatory T cells. Int Immunopharmacol. 2022;104:108469.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"705_CR35","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","volume":"41","author":"C Tay","year":"2023","unstructured":"Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell. 2023;41(3):450\u201365.","journal-title":"Cancer Cell"},{"issue":"3","key":"705_CR36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ccell.2020.07.004","volume":"38","author":"M de Miguel","year":"2020","unstructured":"de Miguel M, Calvo E. Clinical challenges of immune checkpoint inhibitors. Cancer Cell. 2020;38(3):326\u201333.","journal-title":"Cancer Cell"},{"issue":"1","key":"705_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40164-022-00277-y","volume":"11","author":"Q Jia","year":"2022","unstructured":"Jia Q, Wang A, Yuan Y, Zhu B, Long H. Heterogeneity of the tumor immune microenvironment and its clinical relevance. Exp Hematol Oncol. 2022;11(1):24.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"705_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-022-00363-1","volume":"12","author":"L Guo","year":"2023","unstructured":"Guo L, Kong D, Liu J, Zhan L, Luo L, Zheng W, et al. Breast cancer heterogeneity and its implication in personalized precision therapy. Exp Hematol Oncol. 2023;12(1):3.","journal-title":"Exp Hematol Oncol"},{"issue":"8","key":"705_CR39","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345\u201356.","journal-title":"Nat Med"},{"issue":"1","key":"705_CR40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","volume":"23","author":"HE Marei","year":"2023","unstructured":"Marei HE, Hasan A, Pozzoli G, Cenciarelli C. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int. 2023;23(1):64.","journal-title":"Cancer Cell Int"},{"key":"705_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07350-w","author":"G Sferruzza","year":"2024","unstructured":"Sferruzza G, Consoli S, Dono F, Evangelista G, Giugno A, Pronello E, et al. A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives. Neurol Sci. 2024. https:\/\/doi.org\/10.1007\/s10072-024-07350-w.","journal-title":"Neurol Sci"},{"key":"705_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100709","volume":"45","author":"JP Bewersdorf","year":"2021","unstructured":"Bewersdorf JP, Shallis RM, Zeidan AM. Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1\/PD-L1 and CTLA-4 pathways. Blood Rev. 2021;45:100709.","journal-title":"Blood Rev"},{"key":"705_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100718","volume":"53","author":"E P\u00e9rez-Ruiz","year":"2020","unstructured":"P\u00e9rez-Ruiz E, Melero I, Kopecka J, Sarmento-Ribeiro AB, Garc\u00eda-Aranda M, De Las RJ. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Drug Resist Updates. 2020;53:100718.","journal-title":"Drug Resist Updates"},{"issue":"7","key":"705_CR44","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.3390\/cancers12071826","volume":"12","author":"E Alard","year":"2020","unstructured":"Alard E, Butnariu A-B, Grillo M, Kirkham C, Zinovkin DA, Newnham L, et al. Advances in anti-cancer immunotherapy: Car-T cell, checkpoint inhibitors, dendritic cell vaccines, and oncolytic viruses, and emerging cellular and molecular targets. Cancers. 2020;12(7):1826.","journal-title":"Cancers"},{"issue":"14","key":"705_CR45","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.3390\/ijms21145009","volume":"21","author":"C Barbari","year":"2020","unstructured":"Barbari C, Fontaine T, Parajuli P, Lamichhane N, Jakubski S, Lamichhane P, et al. Immunotherapies and combination strategies for immuno-oncology. Int J Mol Sci. 2020;21(14):5009.","journal-title":"Int J Mol Sci"},{"key":"705_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.06.003","author":"A Brandenburg","year":"2024","unstructured":"Brandenburg A, Heine A, Brossart P. Next-generation cancer vaccines and emerging immunotherapy combinations. Trends Cancer. 2024. https:\/\/doi.org\/10.1016\/j.trecan.2024.06.003.","journal-title":"Trends Cancer"},{"issue":"1","key":"705_CR47","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-023-01487-5","volume":"16","author":"M Niu","year":"2023","unstructured":"Niu M, Yi M, Wu Y, Lyu L, He Q, Yang R, et al. Synergistic efficacy of simultaneous anti-TGF-\u03b2\/VEGF bispecific antibody and PD-1 blockade in cancer therapy. J Hematol Oncol. 2023;16(1):94.","journal-title":"J Hematol Oncol"},{"key":"705_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005543","author":"M Yi","year":"2022","unstructured":"Yi M, Wu Y, Niu M, Zhu S, Zhang J, Yan Y, et al. Anti-TGF-\u03b2\/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-005543.","journal-title":"J Immunother Cancer"},{"key":"705_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.961805","volume":"13","author":"C Liu","year":"2022","unstructured":"Liu C, Yang M, Zhang D, Chen M, Zhu D. Clinical cancer immunotherapy: Current progress and prospects. Front Immunol. 2022;13:961805.","journal-title":"Front Immunol"},{"issue":"2","key":"705_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2019.11.010","volume":"225","author":"N Taefehshokr","year":"2020","unstructured":"Taefehshokr N, Baradaran B, Baghbanzadeh A, Taefehshokr S. Promising approaches in cancer immunotherapy. Immunobiology. 2020;225(2):151875.","journal-title":"Immunobiology"},{"issue":"11","key":"705_CR51","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s12094-020-02344-4","volume":"22","author":"A Rodriguez Perez","year":"2020","unstructured":"Rodriguez Perez A, Campillo-Davo D, Van Tendeloo V, Benitez-Ribas D. Cellular immunotherapy: a clinical state-of-the-art of a new paradigm for cancer treatment. Clin Transl Oncol. 2020;22(11):1923\u201337.","journal-title":"Clin Transl Oncol"},{"issue":"9","key":"705_CR52","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1002\/cam4.2949","volume":"9","author":"Y Li","year":"2020","unstructured":"Li Y, Shen Y, Zhao R, Samudio I, Jia W, Bai X, et al. Oncolytic virotherapy in hepato-bilio-pancreatic cancer: The key to breaking the log jam? Cancer Med. 2020;9(9):2943\u201359.","journal-title":"Cancer Med"},{"key":"705_CR53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.coi.2018.03.008","volume":"51","author":"S Chaurasiya","year":"2018","unstructured":"Chaurasiya S, Chen NG, Fong Y. Oncolytic viruses and immunity. Curr Opin Immunol. 2018;51:83\u201390.","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"705_CR54","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/sj.mt.6300108","volume":"15","author":"E Kelly","year":"2007","unstructured":"Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15(4):651\u20139.","journal-title":"Mol Ther"},{"issue":"5","key":"705_CR55","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/jnci\/djj111","volume":"98","author":"K Garber","year":"2006","unstructured":"Garber K. China approves world\u2019s first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006;98(5):298\u2013300.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"705_CR56","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023;8(1):156.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"705_CR57","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","volume":"18","author":"PK Bommareddy","year":"2018","unstructured":"Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018;18(8):498\u2013513.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"705_CR58","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/mt.2013.220","volume":"22","author":"ST Workenhe","year":"2014","unstructured":"Workenhe ST, Mossman KL. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther. 2014;22(2):251\u20136.","journal-title":"Mol Ther"},{"issue":"6","key":"705_CR59","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1158\/2326-6066.CIR-21-0171","volume":"10","author":"A Samson","year":"2022","unstructured":"Samson A, West EJ, Carmichael J, Scott KJ, Turnbull S, Kuszlewicz B, et al. Neoadjuvant intravenous oncolytic vaccinia virus therapy promotes anticancer immunity in patients. Cancer Immunol Res. 2022;10(6):745\u201356.","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"705_CR60","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2217\/imt.15.90","volume":"7","author":"C Al Yaghchi","year":"2015","unstructured":"Al Yaghchi C, Zhang Z, Alusi G, Lemoine NR, Wang Y. Vaccinia virus, a promising new therapeutic agent for pancreatic cancer. Immunotherapy. 2015;7(12):1249\u201358.","journal-title":"Immunotherapy"},{"issue":"4","key":"705_CR61","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1158\/0008-5472.CAN-12-2687","volume":"73","author":"CJ Breitbach","year":"2013","unstructured":"Breitbach CJ, Arulanandam R, De Silva N, Thorne SH, Patt R, Daneshmand M, et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res. 2013;73(4):1265\u201375.","journal-title":"Cancer Res"},{"issue":"8","key":"705_CR62","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1442169","volume":"7","author":"S Gujar","year":"2018","unstructured":"Gujar S, Pol JG, Kroemer G. Heating it up: Oncolytic viruses make tumors \u201chot\u201d and suitable for checkpoint blockade immunotherapies. Oncoimmunology. 2018;7(8):e1442169.","journal-title":"Oncoimmunology"},{"issue":"21","key":"705_CR63","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385.","journal-title":"N Engl J Med"},{"issue":"17","key":"705_CR64","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","volume":"387","author":"ND Gross","year":"2022","unstructured":"Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. 2022;387(17):1557\u201368.","journal-title":"N Engl J Med"},{"issue":"4","key":"705_CR65","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566\u201376.","journal-title":"Nat Med"},{"issue":"226","key":"705_CR66","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008095","volume":"6","author":"D Zamarin","year":"2014","unstructured":"Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014;6(226):226ra232-226ra232.","journal-title":"Sci Transl Med"},{"key":"705_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041295","author":"ME Davola","year":"2023","unstructured":"Davola ME, Cormier O, Vito A, El-Sayes N, Collins S, Salem O, et al. Oncolytic BHV-1 is sufficient to induce immunogenic cell death and synergizes with low-dose chemotherapy to dampen immunosuppressive T regulatory cells. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15041295.","journal-title":"Cancers (Basel)"},{"key":"705_CR68","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004762","author":"F Ju","year":"2022","unstructured":"Ju F, Luo Y, Lin C, Jia X, Xu Z, Tian R, et al. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-004762.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"705_CR69","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017;170(6):1109-1119.e1110.","journal-title":"Cell"},{"issue":"19","key":"705_CR70","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1158\/1078-0432.CCR-20-1170","volume":"26","author":"KJ Harrington","year":"2020","unstructured":"Harrington KJ, Kong A, Mach N, Chesney JA, Fernandez BC, Rischin D, et al. Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. Clin Cancer Res. 2020;26(19):5153\u201361.","journal-title":"Clin Cancer Res"},{"key":"705_CR71","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006561","author":"M Fakih","year":"2023","unstructured":"Fakih M, Harb W, Mahadevan D, Babiker H, Berlin J, Lillie T, et al. Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced\/metastatic epithelial cancer: a phase i clinical trial (SPICE). J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-006561.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"705_CR72","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40169-018-0214-5","volume":"7","author":"CJ LaRocca","year":"2018","unstructured":"LaRocca CJ, Warner SG. Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials. Clin Transl Med. 2018;7(1):35.","journal-title":"Clin Transl Med"},{"key":"705_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005007","author":"CM Rudin","year":"2023","unstructured":"Rudin CM, Pandha HS, Zibelman M, Akerley WL, Harrington KJ, Day D, et al. Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-005007.","journal-title":"J Immunother Cancer"},{"key":"705_CR74","doi-asserted-by":"publisher","first-page":"S868","DOI":"10.1016\/j.annonc.2021.08.1422","volume":"32","author":"A Ribas","year":"2021","unstructured":"Ribas A, Chesney J, Long GV, Kirkwood JM, Dummer R, Puzanov I, et al. 1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB\u2013IVM1c melanoma (MEL). Ann Oncol. 2021;32:S868\u20139.","journal-title":"Ann Oncol"},{"issue":"Pt 3","key":"705_CR75","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.semcancer.2021.05.019","volume":"86","author":"HM Nguyen","year":"2022","unstructured":"Nguyen HM, Bommareddy PK, Silk AW, Saha D. Optimal timing of PD-1 blockade in combination with oncolytic virus therapy. Semin Cancer Biol. 2022;86(Pt 3):971\u201380.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"705_CR76","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/1078-0432.CCR-22-2046","volume":"29","author":"AN Shoushtari","year":"2023","unstructured":"Shoushtari AN, Olszanski AJ, Nyakas M, Hornyak TJ, Wolchok JD, Levitsky V, et al. Pilot study of ONCOS-102 and pembrolizumab: remodeling of the tumor microenvironment and clinical outcomes in anti-PD-1-resistant advanced melanoma. Clin Cancer Res. 2023;29(1):100\u20139.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"705_CR77","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1158\/2326-6066.CIR-20-0609","volume":"9","author":"BB Haines","year":"2021","unstructured":"Haines BB, Denslow A, Grzesik P, Lee JS, Farkaly T, Hewett J, et al. ONCR-177, an oncolytic HSV-1 designed to potently activate systemic antitumor immunity. Cancer Immunol Res. 2021;9(3):291\u2013308.","journal-title":"Cancer Immunol Res"},{"issue":"15","key":"705_CR78","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1158\/0008-5472.CAN-16-2165","volume":"77","author":"L Fend","year":"2017","unstructured":"Fend L, Yamazaki T, Remy C, Fahrner C, Gantzer M, Nourtier V, et al. Immune checkpoint blockade, immunogenic chemotherapy or IFN-\u03b1 blockade boost the local and abscopal effects of oncolytic virotherapy. Cancer Res. 2017;77(15):4146\u201357.","journal-title":"Cancer Res"},{"issue":"1","key":"705_CR79","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40164-024-00536-0","volume":"13","author":"D Zhou","year":"2024","unstructured":"Zhou D, Zhu X, Xiao Y. CAR-T cell combination therapies in hematologic malignancies. Exp Hematol Oncol. 2024;13(1):69.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"705_CR80","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22(1):40.","journal-title":"Mol Cancer"},{"issue":"1","key":"705_CR81","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","volume":"7","author":"DR Wang","year":"2022","unstructured":"Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther. 2022;7(1):331.","journal-title":"Signal Transduct Target Ther"},{"issue":"Pt 2","key":"705_CR82","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.semcancer.2018.05.005","volume":"52","author":"D Atanackovic","year":"2018","unstructured":"Atanackovic D, Luetkens T. Biomarkers for checkpoint inhibition in hematologic malignancies. Semin Cancer Biol. 2018;52(Pt 2):198\u2013206.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"705_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02778-6","volume":"22","author":"M Al-Haideri","year":"2022","unstructured":"Al-Haideri M, Tondok SB, Safa SH, maleki AH, Rostami S, Jalil AT, et al. CAR-T cell combination therapy: the next revolution in cancer treatment. Cancer Cell Int. 2022;22(1):365.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"705_CR84","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12943-023-01775-1","volume":"22","author":"L Hovhannisyan","year":"2023","unstructured":"Hovhannisyan L, Riether C, Aebersold DM, Medov\u00e1 M, Zimmer Y. CAR t cell-based immunotherapy and radiation therapy: potential, promises and risks. Mol Cancer. 2023;22(1):82.","journal-title":"Mol Cancer"},{"issue":"4","key":"705_CR85","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"key":"705_CR86","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006290","author":"L Magr\u00e9","year":"2023","unstructured":"Magr\u00e9 L, Verstegen MMA, Buschow S, van der Laan LJW, Peppelenbosch M, Desai J. Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-006290.","journal-title":"J Immunother Cancer"},{"key":"705_CR87","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03122-8","author":"F Rababah","year":"2023","unstructured":"Rababah F, Alabduh T, Awawdeh A, Shatnawi T, Al-Shdaifat M, Ibdah E, et al. Chimeric antigen receptor T cells therapy in solid tumors. Clin Transl Oncol. 2023. https:\/\/doi.org\/10.1007\/s12094-023-03122-8.","journal-title":"Clin Transl Oncol"},{"key":"705_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1192506","volume":"14","author":"J Li","year":"2023","unstructured":"Li J, Xuan S, Dong P, Xiang Z, Gao C, Li M, et al. Immunotherapy of hepatocellular carcinoma: recent progress and new strategy. Front Immunol. 2023;14:1192506.","journal-title":"Front Immunol"},{"issue":"6","key":"705_CR89","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.trecan.2023.02.004","volume":"9","author":"L Lybaert","year":"2023","unstructured":"Lybaert L, Thielemans K, Feldman SA, van der Burg SH, Bogaert C, Ott PA. Neoantigen-directed therapeutics in the clinic: where are we? Trends Cancer. 2023;9(6):503\u201319.","journal-title":"Trends Cancer"},{"issue":"9","key":"705_CR90","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2017;23(9):2255\u201366.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"705_CR91","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.ymthe.2021.01.021","volume":"29","author":"F Zou","year":"2021","unstructured":"Zou F, Tan J, Liu T, Liu B, Tang Y, Zhang H, et al. The CD39(+) HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8(+) T cells exhibit potent anti-HCC activity. Mol Ther. 2021;29(5):1794\u2013807.","journal-title":"Mol Ther"},{"key":"705_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101663","volume":"32","author":"G Zhang","year":"2023","unstructured":"Zhang G, Zhao Y, Liu Z, Liu W, Wu H, Wang X, et al. GD2 CAR-T cells in combination with Nivolumab exhibit enhanced antitumor efficacy. Transl Oncol. 2023;32:101663.","journal-title":"Transl Oncol"},{"issue":"6","key":"705_CR93","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129(6):2210\u201321.","journal-title":"J Clin Invest"},{"issue":"16","key":"705_CR94","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017;35(16):1803\u201313.","journal-title":"J Clin Oncol"},{"issue":"5","key":"705_CR95","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","volume":"18","author":"G Liu","year":"2021","unstructured":"Liu G, Rui W, Zhao X, Lin X. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol Immunol. 2021;18(5):1085\u201395.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"705_CR96","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","volume":"13","author":"S Zheng","year":"2024","unstructured":"Zheng S, Wang W, Shen L, Yao Y, Xia W, Ni C. Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies. Exp Hematol Oncol. 2024;13(1):80.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"705_CR97","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40164-024-00539-x","volume":"13","author":"Y Yin","year":"2024","unstructured":"Yin Y, Feng W, Chen J, Chen X, Wang G, Wang S, et al. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside. Exp Hematol Oncol. 2024;13(1):72.","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"705_CR98","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00262-015-1692-6","volume":"64","author":"RA Burga","year":"2015","unstructured":"Burga RA, Thorn M, Point GR, Guha P, Nguyen CT, Licata LA, et al. Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother. 2015;64(7):817\u201329.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"705_CR99","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","volume":"39","author":"S Srivastava","year":"2021","unstructured":"Srivastava S, Furlan SN, Jaeger-Ruckstuhl CA, Sarvothama M, Berger C, Smythe KS, et al. Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade. Cancer Cell. 2021;39(2):193-208.e110.","journal-title":"Cancer Cell"},{"issue":"1","key":"705_CR100","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","volume":"25","author":"S Mohammed","year":"2017","unstructured":"Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, Rooney CM, et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol Ther. 2017;25(1):249\u201358.","journal-title":"Mol Ther"},{"issue":"7","key":"705_CR101","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","volume":"5","author":"G Krenciute","year":"2017","unstructured":"Krenciute G, Prinzing BL, Yi Z, Wu M-F, Liu H, Dotti G, et al. Transgenic expression of IL15 improves antiglioma activity of IL13R\u03b12-CAR T cells but results in antigen loss variants. Cancer Immunol Res. 2017;5(7):571\u201381.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"705_CR102","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.994446","volume":"4","author":"M Koneru","year":"2015","unstructured":"Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015;4(3):e994446.","journal-title":"Oncoimmunology"},{"key":"705_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1018903","volume":"13","author":"Z Jin","year":"2022","unstructured":"Jin Z, Sun X, Wang Y, Zhou C, Yang H, Zhou S. Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy. Front Immunol. 2022;13:1018903.","journal-title":"Front Immunol"},{"key":"705_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1045024","volume":"14","author":"K Zhang","year":"2023","unstructured":"Zhang K, Chen H, Li F, Huang S, Chen F, Li Y. Bright future or blind alley? CAR-T cell therapy for solid tumors. Front Immunol. 2023;14:1045024.","journal-title":"Front Immunol"},{"key":"705_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738456","volume":"12","author":"N Ghahri-Saremi","year":"2021","unstructured":"Ghahri-Saremi N, Akbari B, Soltantoyeh T, Hadjati J, Ghassemi S, Mirzaei HR. Genetic modification of cytokine signaling to enhance efficacy of CAR T cell therapy in solid tumors. Front Immunol. 2021;12:738456.","journal-title":"Front Immunol"},{"issue":"8","key":"705_CR106","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130\u201344.","journal-title":"J Clin Invest"},{"issue":"6","key":"705_CR107","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/mt.2016.63","volume":"24","author":"T Gargett","year":"2016","unstructured":"Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, et al. GD2-specific CAR t cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol Ther. 2016;24(6):1135\u201349.","journal-title":"Mol Ther"},{"key":"705_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044197","author":"K Cheng","year":"2023","unstructured":"Cheng K, Feng X, Chai Z, Wang Z, Liu Z, Yan Z, et al. 4\u20131BB-based CAR t cells effectively reverse exhaustion and enhance the anti-tumor immune response through autocrine PD-L1 scFv antibody. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24044197.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"705_CR109","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00542-2","volume":"13","author":"X Gu","year":"2024","unstructured":"Gu X, Zhang Y, Zhou W, Wang F, Yan F, Gao H, et al. Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers. Exp Hematol Oncol. 2024;13(1):70.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"705_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00535-1","volume":"13","author":"A Van der Vreken","year":"2024","unstructured":"Van der Vreken A, Vanderkerken K, De Bruyne E, De Veirman K, Breckpot K, Menu E. Fueling CARs: metabolic strategies to enhance CAR T-cell therapy. Exp Hematol Oncol. 2024;13(1):66.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"705_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00564-w","volume":"13","author":"X Li","year":"2024","unstructured":"Li X, Chen T, Li X, Zhang H, Li Y, Zhang S, et al. Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment. Exp Hematol Oncol. 2024;13(1):96.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"705_CR112","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00580-w","volume":"13","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Xu Q, Gao Z, Zhang H, Xie X, Li M. High-throughput screening for optimizing adoptive T cell therapies. Exp Hematol Oncol. 2024;13(1):113.","journal-title":"Exp Hematol Oncol"},{"key":"705_CR113","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.phrs.2017.11.035","volume":"129","author":"MC Ramello","year":"2018","unstructured":"Ramello MC, Haura EB, Abate-Daga D. CAR-T cells and combination therapies: what\u2019s next in the immunotherapy revolution? Pharmacol Res. 2018;129:194\u2013203.","journal-title":"Pharmacol Res"},{"issue":"7","key":"705_CR114","first-page":"1979","volume":"10","author":"M Huang","year":"2020","unstructured":"Huang M, Deng J, Gao L, Zhou J. Innovative strategies to advance CAR T cell therapy for solid tumors. Am J Cancer Res. 2020;10(7):1979\u201392.","journal-title":"Am J Cancer Res"},{"issue":"9","key":"705_CR115","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","volume":"25","author":"A Heczey","year":"2017","unstructured":"Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, et al. CAR t cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol Ther. 2017;25(9):2214\u201324.","journal-title":"Mol Ther"},{"issue":"11","key":"705_CR116","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli PS, Zauderer MG, Rivi\u00e8re I, Solomon SB, Rusch VW, O\u2019Cearbhaill RE, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 2021;11(11):2748\u201363.","journal-title":"Cancer Discov"},{"key":"705_CR117","doi-asserted-by":"crossref","unstructured":"Bagley S, Binder Z, Desai A, Nasrallah M, Maloney E, Brem S, Lustig R, Kurtz G, Alonso-Basanta M, Mohan S et al. Phase I study of repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab in patients with newly diagnosed, MGMT-unmethylated glioblastoma; 2023.","DOI":"10.21203\/rs.3.rs-2742648\/v1"},{"issue":"11","key":"705_CR118","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/jjco\/hyaa164","volume":"50","author":"T Nejo","year":"2020","unstructured":"Nejo T, Mende A, Okada H. The current state of immunotherapy for primary and secondary brain tumors: similarities and differences. Jpn J Clin Oncol. 2020;50(11):1231\u201345.","journal-title":"Jpn J Clin Oncol"},{"issue":"7","key":"705_CR119","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.tibs.2023.03.004","volume":"48","author":"S Cadenas-De Miguel","year":"2023","unstructured":"Cadenas-De Miguel S, Lucianer G, Elia I. The metabolic cross-talk between cancer and T cells. Trends Biochem Sci. 2023;48(7):597\u2013609.","journal-title":"Trends Biochem Sci"},{"issue":"2","key":"705_CR120","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrc3670","volume":"14","author":"PG Coulie","year":"2014","unstructured":"Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14(2):135\u201346.","journal-title":"Nat Rev Cancer"},{"issue":"Pt 23","key":"705_CR121","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1242\/jcs.116392","volume":"125","author":"FR Balkwill","year":"2012","unstructured":"Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125(Pt 23):5591\u20136.","journal-title":"J Cell Sci"},{"key":"705_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110873","volume":"132","author":"B Lin","year":"2020","unstructured":"Lin B, Du L, Li H, Zhu X, Cui L, Li X. Tumor-infiltrating lymphocytes: warriors fight against tumors powerfully. Biomed Pharmacother. 2020;132:110873.","journal-title":"Biomed Pharmacother"},{"key":"705_CR123","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2428","author":"TJ Monberg","year":"2023","unstructured":"Monberg TJ, Borch TH, Svane IM, Donia M. Til therapy: facts and hopes. Clin Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2428.","journal-title":"Clin Cancer Res"},{"key":"705_CR124","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002723","author":"K Kirtane","year":"2021","unstructured":"Kirtane K, Elmariah H, Chung CH, Abate-Daga D. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-002723.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"705_CR125","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CJI.0b013e3181f05b91","volume":"33","author":"SL Goff","year":"2010","unstructured":"Goff SL, Smith FO, Klapper JA, Sherry R, Wunderlich JR, Steinberg SM, et al. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother. 2010;33(8):840\u20137.","journal-title":"J Immunother"},{"issue":"1","key":"705_CR126","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02006-4","volume":"19","author":"S Wang","year":"2021","unstructured":"Wang S, Sun J, Chen K, Ma P, Lei Q, Xing S, et al. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors. BMC Med. 2021;19(1):140.","journal-title":"BMC Med"},{"issue":"10","key":"705_CR127","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","volume":"29","author":"A Betof Warner","year":"2023","unstructured":"Betof Warner A, Corrie PG, Hamid O. Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future. Clin Cancer Res. 2023;29(10):1835\u201354.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"705_CR128","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1053\/j.gastro.2017.06.017","volume":"153","author":"G Zhou","year":"2017","unstructured":"Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, et al. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Gastroenterology. 2017;153(4):1107-1119.e1110.","journal-title":"Gastroenterology"},{"issue":"1","key":"705_CR129","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1736792","volume":"9","author":"N Gestermann","year":"2020","unstructured":"Gestermann N, Saugy D, Martignier C, Till\u00e9 L, Fuertes Marraco SA, Zettl M, et al. LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma\/T cell co-cultures. Oncoimmunology. 2020;9(1):1736792.","journal-title":"Oncoimmunology"},{"key":"705_CR130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00385","volume":"9","author":"FS Lichtenegger","year":"2018","unstructured":"Lichtenegger FS, Rothe M, Schnorfeil FM, Deiser K, Krupka C, Augsberger C, et al. Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells. Front Immunol. 2018;9:385.","journal-title":"Front Immunol"},{"issue":"1","key":"705_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60738-4","volume":"10","author":"C Friese","year":"2020","unstructured":"Friese C, Harbst K, Borch TH, Westergaard MCW, Pedersen M, Kverneland A, et al. CTLA-4 blockade boosts the expansion of tumor-reactive CD8(+) tumor-infiltrating lymphocytes in ovarian cancer. Sci Rep. 2020;10(1):3914.","journal-title":"Sci Rep"},{"issue":"2","key":"705_CR132","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1158\/0008-5472.CAN-13-2752","volume":"74","author":"J Duraiswamy","year":"2014","unstructured":"Duraiswamy J, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors\u2014response. Cancer Res. 2014;74(2):633\u20134.","journal-title":"Cancer Res"},{"issue":"4","key":"705_CR133","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1158\/0008-5472.CAN-11-2637","volume":"72","author":"J Fourcade","year":"2012","unstructured":"Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 2012;72(4):887\u201396.","journal-title":"Cancer Res"},{"key":"705_CR134","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/cells10092234","volume":"10","author":"A Beumer-Chuwonpad","year":"2021","unstructured":"Beumer-Chuwonpad A, Taggenbrock R, Ngo TA, van Gisbergen K. The potential of tissue-resident memory T cells for adoptive immunotherapy against cancer. Cells. 2021;10:9.","journal-title":"Cells"},{"issue":"4","key":"705_CR135","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jhep.2019.05.026","volume":"71","author":"G Zhou","year":"2019","unstructured":"Zhou G, Sprengers D, Mancham S, Erkens R, Boor PPC, van Beek AA, et al. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules. J Hepatol. 2019;71(4):753\u201362.","journal-title":"J Hepatol"},{"issue":"8","key":"705_CR136","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021;27(8):1410\u20138.","journal-title":"Nat Med"},{"issue":"16","key":"705_CR137","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1200\/JCO.21.02170","volume":"40","author":"N Zacharakis","year":"2022","unstructured":"Zacharakis N, Huq LM, Seitter SJ, Kim SP, Gartner JJ, Sindiri S, et al. Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes. J Clin Oncol. 2022;40(16):1741\u201354.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"705_CR138","volume":"36","author":"SM Lee","year":"2018","unstructured":"Lee SM, Haigentz M, Villaruz LC, Gorbatchevsky I, Suzuki S, Tanamly S, et al. A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (TIL, LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC. J Clin Oncol. 2018;36(15_suppl):TPS3107-TPS3107.","journal-title":"J Clin Oncol"},{"key":"705_CR139","first-page":"1","volume":"1","author":"DA Musa","year":"2024","unstructured":"Musa DA, Raji MO, Sikiru AB, Aremu KH, Aigboeghian EA. Promising RNA-based therapies for Viral infections, Genetic Disorders and Cancer. Acad Mol Biol and Genomics. 2024;1:1.","journal-title":"Acad Mol Biol and Genomics."},{"issue":"3","key":"705_CR140","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168\u201382.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"705_CR141","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040776","volume":"8","author":"A Esprit","year":"2020","unstructured":"Esprit A, de Mey W, Bahadur Shahi R, Thielemans K, Franceschini L, Breckpot K. Neo-antigen mRNA vaccines. Vaccines. 2020;8(4):776.","journal-title":"Vaccines"},{"key":"705_CR142","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.663264","volume":"11","author":"JY Liao","year":"2021","unstructured":"Liao JY, Zhang S. Safety and efficacy of personalized cancer vaccines in combination with immune checkpoint inhibitors in cancer treatment. Front Oncol. 2021;11:663264.","journal-title":"Front Oncol"},{"issue":"5","key":"705_CR143","doi-asserted-by":"publisher","first-page":"349","DOI":"10.5582\/bst.2020.03267","volume":"14","author":"C Sun","year":"2020","unstructured":"Sun C, Xu S. Advances in personalized neoantigen vaccines for cancer immunotherapy. Biosci Trends. 2020;14(5):349\u201353.","journal-title":"Biosci Trends"},{"issue":"1","key":"705_CR144","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1055-6","volume":"18","author":"M Peng","year":"2019","unstructured":"Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18(1):128.","journal-title":"Mol Cancer"},{"issue":"12","key":"705_CR145","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw6071","volume":"6","author":"Q Ni","year":"2020","unstructured":"Ni Q, Zhang F, Liu Y, Wang Z, Yu G, Liang B, et al. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer. Sci Adv. 2020;6(12):eaaw6071.","journal-title":"Sci Adv"},{"issue":"11","key":"705_CR146","doi-asserted-by":"publisher","first-page":"1652539","DOI":"10.1080\/2162402X.2019.1652539","volume":"8","author":"E Tondini","year":"2019","unstructured":"Tondini E, Arakelian T, Oosterhuis K, Camps M, van Duikeren S, Han W, et al. A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control. Oncoimmunology. 2019;8(11):1652539.","journal-title":"Oncoimmunology"},{"issue":"1","key":"705_CR147","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41541-022-00433-9","volume":"7","author":"E Salvatori","year":"2022","unstructured":"Salvatori E, Lione L, Compagnone M, Pinto E, Conforti A, Ciliberto G, et al. Neoantigen cancer vaccine augments anti-CTLA-4 efficacy. NPJ Vaccines. 2022;7(1):15.","journal-title":"NPJ Vaccines"},{"issue":"9","key":"705_CR148","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/neuonc\/noaa050","volume":"22","author":"CJ Liu","year":"2020","unstructured":"Liu CJ, Schaettler M, Blaha DT, Bowman-Kirigin JA, Kobayashi DK, Livingstone AJ, et al. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine. Neuro Oncol. 2020;22(9):1276\u201388.","journal-title":"Neuro Oncol"},{"issue":"1","key":"705_CR149","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1038\/s41467-019-10594-2","volume":"10","author":"AM D'Alise","year":"2019","unstructured":"D\u2019Alise AM, Leoni G, Cotugno G, Troise F, Langone F, Fichera I, et al. Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade. Nat Commun. 2019;10(1):2688.","journal-title":"Nat Commun"},{"issue":"2","key":"705_CR150","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell. 2020;183(2):347-362.e324.","journal-title":"Cell"},{"issue":"16_Supplement","key":"705_CR151","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-CT301","volume":"80","author":"JS Lopez","year":"2020","unstructured":"Lopez JS, Camidge R, Iafolla M, Rottey S, Schuler M, Hellmann M, et al. Abstract CT301: a phase Ib study to evaluate RO7198457, an individualized neoantigen specific immunotherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. Cancer Res. 2020;80(16_Supplement):CT301-CT301.","journal-title":"Cancer Res"},{"issue":"Suppl 3","key":"705_CR152","first-page":"A477","volume":"8","author":"J Bauman","year":"2020","unstructured":"Bauman J, Burris H, Clarke J, Patel M, Cho D, Gutierrez M, et al. 798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update. J Immunother Cancer. 2020;8(Suppl 3):A477\u2013A477.","journal-title":"J Immunother Cancer"},{"key":"705_CR153","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14081940","author":"N Mensali","year":"2022","unstructured":"Mensali N, Inderberg EM. Emerging biomarkers for immunotherapy in glioblastoma. Cancers. 2022. https:\/\/doi.org\/10.3390\/cancers14081940.","journal-title":"Cancers"},{"issue":"1","key":"705_CR154","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00506-6","volume":"13","author":"MY Xu","year":"2024","unstructured":"Xu MY, Zeng N, Liu CQ, Sun JX, An Y, Zhang SH, et al. Enhanced cellular therapy: revolutionizing adoptive cellular therapy. Exp Hematol Oncol. 2024;13(1):47.","journal-title":"Exp Hematol Oncol"},{"key":"705_CR155","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.687822","volume":"12","author":"L Miao","year":"2021","unstructured":"Miao L, Zhang Z, Ren Z, Tang F, Li Y. Obstacles and coping strategies of CAR-T cell immunotherapy in solid tumors. Front Immunol. 2021;12:687822.","journal-title":"Front Immunol"},{"issue":"18","key":"705_CR156","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-14-0697","volume":"74","author":"N Nishio","year":"2014","unstructured":"Nishio N, Diaconu I, Liu H, Cerullo V, Caruana I, Hoyos V, et al. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res. 2014;74(18):5195\u2013205.","journal-title":"Cancer Res"},{"issue":"3","key":"705_CR157","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1395997","volume":"7","author":"EK Moon","year":"2018","unstructured":"Moon EK, Wang LS, Bekdache K, Lynn RC, Lo A, Thorne SH, et al. Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. Oncoimmunology. 2018;7(3):e1395997.","journal-title":"Oncoimmunology"},{"key":"705_CR158","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99573","author":"K Watanabe","year":"2018","unstructured":"Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.99573.","journal-title":"JCI Insight"},{"key":"705_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104041","volume":"348","author":"Y Li","year":"2020","unstructured":"Li Y, Xiao F, Zhang A, Zhang D, Nie W, Xu T, et al. Oncolytic adenovirus targeting TGF-\u03b2 enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer. Cell Immunol. 2020;348:104041.","journal-title":"Cell Immunol"},{"issue":"9","key":"705_CR160","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1007\/s00262-021-02856-0","volume":"70","author":"J Huang","year":"2021","unstructured":"Huang J, Zheng M, Zhang Z, Tang X, Chen Y, Peng A, et al. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma. Cancer Immunol Immunother. 2021;70(9):2453\u201365.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"705_CR161","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1172\/JCI129204","volume":"130","author":"L Vago","year":"2020","unstructured":"Vago L, Gojo I. Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest. 2020;130(4):1552\u201364.","journal-title":"J Clin Invest"},{"issue":"5","key":"705_CR162","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","volume":"6","author":"A Wing","year":"2018","unstructured":"Wing A, Fajardo CA, Posey AD Jr., Shaw C, Da T, Young RM, et al. Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager. Cancer Immunol Res. 2018;6(5):605\u201316.","journal-title":"Cancer Immunol Res"},{"key":"705_CR163","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz1863","author":"AK Park","year":"2020","unstructured":"Park AK, Fong Y, Kim SI, Yang J, Murad JP, Lu J, et al. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Sci Transl Med. 2020. https:\/\/doi.org\/10.1126\/scitranslmed.aaz1863.","journal-title":"Sci Transl Med"},{"key":"705_CR164","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0440","author":"UM Lauer","year":"2022","unstructured":"Lauer UM, Beil J. Oncolytic viruses: challenges and considerations in an evolving clinical landscape. Future Oncol. 2022. https:\/\/doi.org\/10.2217\/fon-2022-0440.","journal-title":"Future Oncol"},{"key":"705_CR165","first-page":"234","volume":"15","author":"M Zheng","year":"2019","unstructured":"Zheng M, Huang J, Tong A, Yang H. Oncolytic viruses for cancer therapy: barriers and recent advances. Mol Ther. 2019;15:234\u201347.","journal-title":"Mol Ther"},{"key":"705_CR166","first-page":"1098","volume":"19","author":"S Arya","year":"2020","unstructured":"Arya S, Lin Q, Zhou N, Gao X, Huang JD. Strong immune responses induced by direct local injections of modified mRNA-lipid nanocomplexes. Mol Ther. 2020;19:1098\u2013109.","journal-title":"Mol Ther"},{"issue":"36","key":"705_CR167","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202104068","volume":"31","author":"P Xiao","year":"2021","unstructured":"Xiao P, Wang J, Fang L, Zhao Z, Sun X, Liu X, et al. Nanovaccine-mediated cell selective delivery of neoantigens potentiating adoptive dendritic cell transfer for personalized immunization. Adv Funct Mater. 2021;31(36):2104068.","journal-title":"Adv Funct Mater"},{"issue":"26","key":"705_CR168","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR t-cell therapy in refractory large b-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"5","key":"705_CR169","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"key":"705_CR170","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0230-9","volume":"5","author":"I Scarf\u00f2","year":"2017","unstructured":"Scarf\u00f2 I, Maus MV. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J Immunother Cancer. 2017;5:28.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"705_CR171","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00336-1","volume":"6","author":"I McDonald","year":"2021","unstructured":"McDonald I, Murray SM, Reynolds CJ, Altmann DM, Boyton RJ. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. NPJ Vaccines. 2021;6(1):74.","journal-title":"NPJ Vaccines"},{"issue":"23","key":"705_CR172","doi-asserted-by":"publisher","first-page":"5824","DOI":"10.1016\/j.cell.2021.09.033","volume":"184","author":"LD Cruz-Zaragoza","year":"2021","unstructured":"Cruz-Zaragoza LD, Dennerlein S, Linden A, Yousefi R, Lavdovskaia E, Aich A, et al. An in vitro system to silence mitochondrial gene expression. Cell. 2021;184(23):5824-5837.e5815.","journal-title":"Cell"},{"key":"705_CR173","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-018-0494-5","author":"X Yang","year":"2018","unstructured":"Yang X, Liu G, Zang L, Li D, Yu F, Xiang X, et al. ZNF703 is overexpressed in papillary thyroid carcinoma tissues and mediates K1 cell proliferation. Pathol Oncol Res. 2018. https:\/\/doi.org\/10.1007\/s12253-018-0494-5.","journal-title":"Pathol Oncol Res"},{"issue":"7776","key":"705_CR174","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","volume":"574","author":"O Demaria","year":"2019","unstructured":"Demaria O, Cornen S, Da\u00ebron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45\u201356.","journal-title":"Nature"},{"issue":"6476","key":"705_CR175","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1126\/science.aay5967","volume":"367","author":"K Reinhard","year":"2020","unstructured":"Reinhard K, Rengstl B, Oehm P, Michel K, Billmeier A, Hayduk N, et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science. 2020;367(6476):446\u201353.","journal-title":"Science"},{"issue":"6449","key":"705_CR176","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1126\/science.aav8692","volume":"365","author":"L Ma","year":"2019","unstructured":"Ma L, Dichwalkar T, Chang JYH, Cossette B, Garafola D, Zhang AQ, et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science. 2019;365(6449):162\u20138.","journal-title":"Science"},{"key":"705_CR177","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02612-0","author":"A Mackensen","year":"2023","unstructured":"Mackensen A, Haanen J, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023. https:\/\/doi.org\/10.1038\/s41591-023-02612-0.","journal-title":"Nat Med"},{"key":"705_CR178","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.635527","volume":"9","author":"T Marchini","year":"2021","unstructured":"Marchini T, Mitre LS, Wolf D. Inflammatory cell recruitment in cardiovascular disease. Front Cell Dev Biol. 2021;9:635527.","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"705_CR179","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41569-018-0110-0","volume":"16","author":"PEJ van der Meijden","year":"2019","unstructured":"van der Meijden PEJ, Heemskerk JWM. Platelet biology and functions: new concepts and clinical perspectives. Nat Rev Cardiol. 2019;16(3):166\u201379.","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"705_CR180","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman WH, Zitvogel L, Saut\u00e8s-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717\u201334.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"705_CR181","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41575-021-00568-5","volume":"19","author":"D Geh","year":"2022","unstructured":"Geh D, Leslie J, Rumney R, Reeves HL, Bird TG, Mann DA. Neutrophils as potential therapeutic targets in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2022;19(4):257\u201373.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"16","key":"705_CR182","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood.2023021283","volume":"142","author":"GP Collins","year":"2023","unstructured":"Collins GP. Tackling PD1i resistance in Hodgkin lymphoma. Blood. 2023;142(16):1333\u20134.","journal-title":"Blood"},{"issue":"12","key":"705_CR183","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1016\/j.ymthe.2022.06.010","volume":"30","author":"K Ye","year":"2022","unstructured":"Ye K, Li F, Wang R, Cen T, Liu S, Zhao Z, et al. An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ. Mol Ther. 2022;30(12):3658\u201376.","journal-title":"Mol Ther"},{"key":"705_CR184","doi-asserted-by":"publisher","DOI":"10.3390\/cells10050978","author":"J Santos","year":"2021","unstructured":"Santos J, Heini\u00f6 C, Quixabeira D, Zafar S, Clubb J, Pakola S, et al. Systemic delivery of oncolytic adenovirus to tumors using tumor-infiltrating lymphocytes as carriers. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10050978.","journal-title":"Cells"},{"key":"705_CR185","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000188","author":"JM Santos","year":"2020","unstructured":"Santos JM, Heini\u00f6 C, Cervera-Carrascon V, Quixabeira DCA, Siurala M, Havunen R, et al. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2019-000188.","journal-title":"J Immunother Cancer"},{"issue":"1\u20132","key":"705_CR186","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41417-020-0189-4","volume":"28","author":"M Feist","year":"2021","unstructured":"Feist M, Zhu Z, Dai E, Ma C, Liu Z, Giehl E, et al. Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy. Cancer Gene Ther. 2021;28(1\u20132):98\u2013111.","journal-title":"Cancer Gene Ther"},{"key":"705_CR187","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2024.100726","author":"TJ Monberg","year":"2024","unstructured":"Monberg TJ, Kudling T, Albieri B, Pakola S, Ellebaek E, Donia M, et al. Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma. Immuno-Oncol Technol. 2024. https:\/\/doi.org\/10.1016\/j.iotech.2024.100726.","journal-title":"Immuno-Oncol Technol"},{"key":"705_CR188","first-page":"123","volume":"20","author":"T Monberg","year":"2023","unstructured":"Monberg T, Pakola S, Dreno B, Cervera-Carrascon V, Elleb\u00e6k E, Donia M, et al. 48O Safety and efficacy of combined treatment with tumor infiltrating lymphocytes (TILs) and oncolytic adenovirus TILT-123 for patients with metastatic melanoma: Results from a phase I trial. Immuno-Oncol Technol. 2023;20:123.","journal-title":"Immuno-Oncol Technol"},{"issue":"1","key":"705_CR189","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22115-1","volume":"12","author":"T Kottke","year":"2021","unstructured":"Kottke T, Tonne J, Evgin L, Driscoll CB, van Vloten J, Jennings VA, et al. Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. Nat Commun. 2021;12(1):1930.","journal-title":"Nat Commun"},{"issue":"10","key":"705_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101229","volume":"4","author":"J Dan","year":"2023","unstructured":"Dan J, Cai J, Zhong Y, Wang C, Huang S, Zeng Y, et al. Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine. Cell Rep Med. 2023;4(10):101229.","journal-title":"Cell Rep Med"},{"issue":"15","key":"705_CR191","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","volume":"185","author":"MC Sellars","year":"2022","unstructured":"Sellars MC, Wu CJ, Fritsch EF. Cancer vaccines: building a bridge over troubled waters. Cell. 2022;185(15):2770\u201388.","journal-title":"Cell"},{"issue":"2","key":"705_CR192","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","volume":"9","author":"R Ma","year":"2023","unstructured":"Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2023;9(2):122\u201339.","journal-title":"Trends Cancer"},{"key":"705_CR193","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.707542","volume":"12","author":"MB Khawar","year":"2021","unstructured":"Khawar MB, Sun H. CAR-NK cells: from natural basis to design for kill. Front Immunol. 2021;12:707542.","journal-title":"Front Immunol"},{"issue":"1","key":"705_CR194","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, Farrukh H, Chittepu V, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41(1):119.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"705_CR195","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40164-024-00511-9","volume":"13","author":"J Hou","year":"2024","unstructured":"Hou J, Xie S, Gao J, Jiang T, Zhu E, Yang X, et al. NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice. Exp Hematol Oncol. 2024;13(1):48.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"705_CR196","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40164-024-00504-8","volume":"13","author":"W Shao","year":"2024","unstructured":"Shao W, Yao Y, Yang L, Li X, Ge T, Zheng Y, et al. Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy. Exp Hematol Oncol. 2024;13(1):37.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"705_CR197","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40164-024-00481-y","volume":"13","author":"J Shang","year":"2024","unstructured":"Shang J, Hu S, Wang X. Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies. Exp Hematol Oncol. 2024;13(1):21.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"705_CR198","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40164-024-00561-z","volume":"13","author":"Y Shi","year":"2024","unstructured":"Shi Y, Hao D, Qian H, Tao Z. Natural killer cell-based cancer immunotherapy: from basics to clinical trials. Exp Hematol Oncol. 2024;13(1):101.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"705_CR199","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12943-024-02032-9","volume":"23","author":"N Li","year":"2024","unstructured":"Li N, Geng S, Dong ZZ, Jin Y, Ying H, Li HW, et al. A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy. Mol Cancer. 2024;23(1):117.","journal-title":"Mol Cancer"},{"issue":"3","key":"705_CR200","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145\u201361.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"705_CR201","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00573-9","volume":"13","author":"Y Yang","year":"2024","unstructured":"Yang Y, Peng H, Wang J, Li F. New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies. Exp Hematol Oncol. 2024;13(1):110.","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"705_CR202","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s43018-022-00401-1","volume":"3","author":"MF Sanmamed","year":"2022","unstructured":"Sanmamed MF, Berraondo P, Rodriguez-Ruiz ME, Melero I. Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nat Cancer. 2022;3(6):665\u201380.","journal-title":"Nat Cancer"},{"issue":"3","key":"705_CR203","doi-asserted-by":"publisher","DOI":"10.3390\/cells10030659","volume":"10","author":"HYK Yip","year":"2021","unstructured":"Yip HYK, Papa A. Signaling pathways in cancer: therapeutic targets, combinatorial treatments, and new developments. Cells. 2021;10(3):659.","journal-title":"Cells"},{"issue":"8","key":"705_CR204","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05171-3","volume":"13","author":"Q Sun","year":"2022","unstructured":"Sun Q, Wang Y, Ji H, Sun X, Xie S, Chen L, et al. Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma. Cell Death Dis. 2022;13(8):724.","journal-title":"Cell Death Dis"},{"key":"705_CR205","doi-asserted-by":"publisher","first-page":"112114","DOI":"10.1016\/j.inoche.2024.112114","volume":"161","author":"M Pourmadadi","year":"2024","unstructured":"Pourmadadi M, Mohammadzadeh V, Mohammadi ZS, Poorkhalili P, Afjoul N, Behzadmehr R, et al. Advances in erlotinib delivery systems: Addressing challenges and exploring opportunities in EGFR-targeted cancer therapies. Inorg Chem Commun. 2024;161:112114.","journal-title":"Inorg Chem Commun"},{"issue":"9","key":"705_CR206","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.7150\/ijbs.70958","volume":"18","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Guo S, Deng J, Shen J, Du F, Wu X, et al. VEGF\/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment. Int J Biol Sci. 2022;18(9):3845.","journal-title":"Int J Biol Sci"},{"key":"705_CR207","doi-asserted-by":"publisher","first-page":"175883592090750","DOI":"10.1177\/1758835920907504","volume":"12","author":"E Rassy","year":"2020","unstructured":"Rassy E, Flippot R, Albiges L. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. Ther Adv Med Oncol. 2020;12:1758835920907504.","journal-title":"Ther Adv Med Oncol"},{"key":"705_CR208","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.635007","volume":"11","author":"KK To","year":"2021","unstructured":"To KK, Fong W, Cho WC. Immunotherapy in treating EGFR-mutant lung cancer: current challenges and new strategies. Front Oncol. 2021;11:635007.","journal-title":"Front Oncol"},{"issue":"7","key":"705_CR209","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.3390\/ijms22073765","volume":"22","author":"F Lopes-Coelho","year":"2021","unstructured":"Lopes-Coelho F, Martins F, Pereira SA, Serpa J. Anti-angiogenic therapy: current challenges and future perspectives. Int J Mol Sci. 2021;22(7):3765.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"705_CR210","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1002\/jcb.30344","volume":"123","author":"A Ahmad","year":"2022","unstructured":"Ahmad A, Nawaz MI. Molecular mechanism of VEGF and its role in pathological angiogenesis. J Cell Biochem. 2022;123(12):1938\u201365.","journal-title":"J Cell Biochem"},{"key":"705_CR211","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1423891","volume":"15","author":"Y Xie","year":"2024","unstructured":"Xie Y, Zhou F. Efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials. Front Pharmacol. 2024;15:1423891.","journal-title":"Front Pharmacol"},{"issue":"1","key":"705_CR212","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44875-2","volume":"15","author":"HJ Cho","year":"2024","unstructured":"Cho HJ, Yun K-H, Shin S-J, Lee YH, Kim SH, Baek W, et al. Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial. Nat Commun. 2024;15(1):685.","journal-title":"Nat Commun"},{"issue":"5","key":"705_CR213","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1007\/s00210-023-02781-2","volume":"397","author":"A Sharma","year":"2024","unstructured":"Sharma A, Jasrotia S, Kumar A. Effects of chemotherapy on the immune system: implications for cancer treatment and patient outcomes. Naunyn-Schmiedebergs Arch Pharmacol. 2024;397(5):2551\u201366.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"705_CR214","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-443-16013-4.00020-8","volume-title":"Molecular oncobiology and cancer chemotherapeutics","author":"SS Bhat","year":"2024","unstructured":"Bhat SS, Thanmaya M, Jahagirdar S, Akshatha C, Prasad SK, Sindhu R. Molecular oncobiology and cancer chemotherapeutics. Amsterdam: Elsevier; 2024."},{"key":"705_CR215","first-page":"15","volume":"1","author":"A Nagy","year":"2024","unstructured":"Nagy A, B\u00f6rzsei D, Hoffmann A, T\u00f6r\u00f6k S, Veszelka M, Alm\u00e1si N, et al. A comprehensive overview on chemotherapy-induced cardiotoxicity: insights into the underlying inflammatory and oxidative mechanisms. Cardiov Drugs Therapy. 2024;1:15.","journal-title":"Cardiov Drugs Therapy"},{"issue":"12","key":"705_CR216","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16122288","volume":"16","author":"A Markowska","year":"2024","unstructured":"Markowska A, Antoszczak M, Markowska J, Huczy\u0144ski A. Gynotoxic effects of chemotherapy and potential protective mechanisms. Cancers. 2024;16(12):2288.","journal-title":"Cancers"},{"key":"705_CR217","doi-asserted-by":"publisher","first-page":"217079","DOI":"10.1016\/j.canlet.2024.217079","volume":"598","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Mai Y, Zhang G, Wang Y, Sun P, Jing Z, et al. Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination. Cancer Lett. 2024;598:217079.","journal-title":"Cancer Lett"},{"issue":"10","key":"705_CR218","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.7150\/ijbs.93697","volume":"20","author":"R Birnboim-Perach","year":"2024","unstructured":"Birnboim-Perach R, Benhar I. Using combination therapy to overcome diverse challenges of immune checkpoint inhibitors treatment. Int J Biol Sci. 2024;20(10):3911\u201322.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"705_CR219","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28.","journal-title":"Mol Cancer"},{"issue":"1","key":"705_CR220","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00588-2","volume":"13","author":"MS Kim","year":"2024","unstructured":"Kim MS, Kang H, Baek JH, Cho MG, Chung EJ, Kim SJ, et al. Disrupting notch signaling related HES1 in myeloid cells reinvigorates antitumor T cell responses. Exp Hematol Oncol. 2024;13(1):122.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"705_CR221","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01363-8","volume":"15","author":"M Yi","year":"2022","unstructured":"Yi M, Niu M, Wu Y, Ge H, Jiao D, Zhu S, et al. Combination of oral STING agonist MSA-2 and anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors. J Hematol Oncol. 2022;15(1):142.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"705_CR222","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrd4591","volume":"14","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14(8):561\u201384.","journal-title":"Nat Rev Drug Discov"},{"key":"705_CR223","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ejca.2021.08.004","volume":"157","author":"J Yuan","year":"2021","unstructured":"Yuan J, Khilnani A, Brody J, Andtbacka RH, Hu-Lieskovan S, Luke JJ, et al. Current strategies for intratumoural immunotherapy\u2013beyond immune checkpoint inhibition. Eur J Cancer. 2021;157:493\u2013510.","journal-title":"Eur J Cancer"},{"issue":"4","key":"705_CR224","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2174\/1568009620666200115162814","volume":"20","author":"M Cardano","year":"2020","unstructured":"Cardano M, Tribioli C, Prosperi E. Targeting proliferating cell nuclear antigen (PCNA) as an effective strategy to inhibit tumor cell proliferation. Curr Cancer Drug Targets. 2020;20(4):240\u201352.","journal-title":"Curr Cancer Drug Targets"},{"key":"705_CR225","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109537","author":"Y-L Wang","year":"2021","unstructured":"Wang Y-L, Lee C-C, Shen Y-C, Lin P-L, Wu W-R, Lin Y-Z, et al. Evading immune surveillance via tyrosine phosphorylation of nuclear PCNA. Cell Rep. 2021. https:\/\/doi.org\/10.1016\/j.celrep.2021.109537.","journal-title":"Cell Rep"},{"issue":"8","key":"705_CR226","doi-asserted-by":"publisher","DOI":"10.3390\/genes9080416","volume":"9","author":"D Slade","year":"2018","unstructured":"Slade D. Maneuvers on PCNA rings during DNA replication and repair. Genes. 2018;9(8):416.","journal-title":"Genes"},{"issue":"1","key":"705_CR227","first-page":"229","volume":"29","author":"M Refaat","year":"2023","unstructured":"Refaat M, Elsebai EA. Clinicopathological significance of programed death-ligand-1 (PD-L1) and proliferation cell nuclear antige (PCNA) expression in prostatic carcinoma; an immunohistochemical study. Zagazig Univ Med J. 2023;29(1):229\u201337.","journal-title":"Zagazig Univ Med J"},{"key":"705_CR228","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/00008390-199410000-00004","volume":"4","author":"B Iyengar","year":"1994","unstructured":"Iyengar B. Expression of proliferating cell nuclear antigen (PCNA): proliferative phase functions and malignant transformation of melanocytes. Melanoma Res. 1994;4:293\u2013293.","journal-title":"Melanoma Res"},{"issue":"5","key":"705_CR229","first-page":"1185","volume":"5","author":"M Ikeguchi","year":"1998","unstructured":"Ikeguchi M, Ikeda M, Tatebe S, Maeta M, Kaibara N. Clinical significance of dendritic cell infiltration in esophageal squamous cell carcinoma. Oncol Rep. 1998;5(5):1185\u201394.","journal-title":"Oncol Rep"},{"issue":"3","key":"705_CR230","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/ki.1995.347","volume":"48","author":"HY Lan","year":"1995","unstructured":"Lan HY, Nikolic-Paterson DJ, Mu W, Atkins RC. Local macrophage proliferation in the progression of glomerular and tubulointerstitial injury in rat anti-GBM glomerulonephritis. Kidney Int. 1995;48(3):753\u201360.","journal-title":"Kidney Int"},{"issue":"1","key":"705_CR231","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4871-y","volume":"18","author":"T Yang","year":"2018","unstructured":"Yang T, Zhang W, Wang L, Xiao C, Wang L, Gong Y, et al. Co-culture of dendritic cells and cytokine-induced killer cells effectively suppresses liver cancer stem cell growth by inhibiting pathways in the immune system. BMC Cancer. 2018;18(1):984.","journal-title":"BMC Cancer"},{"issue":"7","key":"705_CR232","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41388-022-02582-6","volume":"42","author":"CR Lemech","year":"2023","unstructured":"Lemech CR, Kichenadasse G, Marschner JP, Alevizopoulos K, Otterlei M, Millward M. ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a phase 1 study. Oncogene. 2023;42(7):541\u20134.","journal-title":"Oncogene"},{"issue":"10","key":"705_CR233","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223894","volume":"14","author":"S Lu","year":"2019","unstructured":"Lu S, Dong Z. Additive effects of a small molecular PCNA inhibitor PCNA-I1S and DNA damaging agents on growth inhibition and DNA damage in prostate and lung cancer cells. PLoS ONE. 2019;14(10):e0223894.","journal-title":"PLoS ONE"},{"issue":"10","key":"705_CR234","doi-asserted-by":"publisher","first-page":"7109","DOI":"10.1074\/jbc.M113.520429","volume":"289","author":"A Inoue","year":"2014","unstructured":"Inoue A, Kikuchi S, Hishiki A, Shao Y, Heath R, Evison BJ, et al. A small molecule inhibitor of monoubiquitinated Proliferating Cell Nuclear Antigen (PCNA) inhibits repair of interstrand DNA cross-link, enhances DNA double strand break, and sensitizes cancer cells to cisplatin. J Biol Chem. 2014;289(10):7109\u201320.","journal-title":"J Biol Chem"},{"issue":"17","key":"705_CR235","doi-asserted-by":"publisher","first-page":"14289","DOI":"10.1074\/jbc.M112.353201","volume":"287","author":"C Punchihewa","year":"2012","unstructured":"Punchihewa C, Inoue A, Hishiki A, Fujikawa Y, Connelly M, Evison B, et al. Identification of small molecule proliferating cell nuclear antigen (PCNA) inhibitor that disrupts interactions with PIP-box proteins and inhibits DNA replication. J Biol Chem. 2012;287(17):14289\u2013300.","journal-title":"J Biol Chem"},{"issue":"17","key":"705_CR236","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.3390\/cancers15174421","volume":"15","author":"J Knaneh","year":"2023","unstructured":"Knaneh J, Hodak E, Fedida-Metula S, Edri A, Eren R, Yoffe Y, et al. mAb14, a monoclonal antibody against cell surface PCNA: A potential tool for sezary syndrome diagnosis and targeted immunotherapy. Cancers. 2023;15(17):4421.","journal-title":"Cancers"},{"issue":"3","key":"705_CR237","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059552","volume":"8","author":"NC Horton","year":"2013","unstructured":"Horton NC, Mathew SO, Mathew PA. Novel interaction between proliferating cell nuclear antigen and HLA I on the surface of tumor cells inhibits NK cell function through NKp44. PLoS ONE. 2013;8(3):e59552.","journal-title":"PLoS ONE"},{"issue":"11","key":"705_CR238","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.4049\/jimmunol.1102267","volume":"187","author":"B Rosental","year":"2011","unstructured":"Rosental B, Brusilovsky M, Hadad U, Oz D, Appel MY, Afergan F, et al. Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol. 2011;187(11):5693\u2013702.","journal-title":"J Immunol"},{"issue":"22","key":"705_CR239","doi-asserted-by":"publisher","first-page":"32933","DOI":"10.18632\/oncotarget.8782","volume":"7","author":"A Shemesh","year":"2016","unstructured":"Shemesh A, Brusilovsky M, Hadad U, Teltsh O, Edri A, Rubin E, et al. Survival in acute myeloid leukemia is associated with NKp44 splice variants. Oncotarget. 2016;7(22):32933\u201345.","journal-title":"Oncotarget"},{"issue":"7","key":"705_CR240","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1158\/2326-6066.CIR-19-0023","volume":"7","author":"K Kundu","year":"2019","unstructured":"Kundu K, Ghosh S, Sarkar R, Edri A, Brusilovsky M, Gershoni-Yahalom O, et al. Inhibition of the NKp44-PCNA immune checkpoint using a mAb to PCNA. Cancer Immunol Res. 2019;7(7):1120\u201334.","journal-title":"Cancer Immunol Res"},{"key":"705_CR241","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23094717","author":"M Iraqi","year":"2022","unstructured":"Iraqi M, Edri A, Greenshpan Y, Goldstein O, Ofir N, Bolel P, et al. Blocking the PCNA\/NKp44 checkpoint to stimulate NK cell responses to multiple myeloma. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23094717.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"705_CR242","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.tips.2014.02.004","volume":"35","author":"SC Wang","year":"2014","unstructured":"Wang SC. PCNA: a silent housekeeper or a potential therapeutic target? Trends Pharmacol Sci. 2014;35(4):178\u201386.","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"705_CR243","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.cellsig.2015.03.009","volume":"27","author":"C Olaisen","year":"2015","unstructured":"Olaisen C, M\u00fcller R, Nedal A, Otterlei M. PCNA-interacting peptides reduce Akt phosphorylation and TLR-mediated cytokine secretion suggesting a role of PCNA in cellular signaling. Cell Signal. 2015;27(7):1478\u201387.","journal-title":"Cell Signal"},{"issue":"8","key":"705_CR244","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1021\/acs.jafc.5b04852","volume":"64","author":"X Jiang","year":"2016","unstructured":"Jiang X, Li T, Liu RH. 2\u03b1-hydroxyursolic acid inhibited cell proliferation and induced apoptosis in MDA-MB-231 human breast cancer cells through the p38\/MAPK signal transduction pathway. J Agric Food Chem. 2016;64(8):1806\u201316.","journal-title":"J Agric Food Chem"},{"issue":"7","key":"705_CR245","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070430","volume":"8","author":"R M\u00fcller","year":"2013","unstructured":"M\u00fcller R, Misund K, Holien T, Bachke S, Gilljam KM, V\u00e5tsveen TK, et al. Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells. PLoS ONE. 2013;8(7):e70430.","journal-title":"PLoS ONE"},{"key":"705_CR246","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/cancers14020289","volume":"14","author":"GL Gravina","year":"2022","unstructured":"Gravina GL, Colapietro A, Mancini A, Rossetti A, Martellucci S, Ventura L, et al. ATX-101, a peptide targeting PCNA, has antitumor efficacy alone or in combination with radiotherapy in murine models of human glioblastoma. Cancers. 2022;14:2.","journal-title":"Cancers"},{"issue":"65","key":"705_CR247","doi-asserted-by":"publisher","first-page":"32448","DOI":"10.18632\/oncotarget.25963","volume":"9","author":"CK S\u00f8gaard","year":"2018","unstructured":"S\u00f8gaard CK, Blindheim A, R\u00f8st LM, Petrovi\u0107 V, Nepal A, Bachke S, et al. Two hits - one stone; increased efficacy of cisplatin-based therapies by targeting PCNA\u2019s role in both DNA repair and cellular signaling. Oncotarget. 2018;9(65):32448\u201365.","journal-title":"Oncotarget"},{"issue":"68","key":"705_CR248","doi-asserted-by":"publisher","first-page":"7185","DOI":"10.18632\/oncotarget.27267","volume":"10","author":"CK S\u00f8gaard","year":"2019","unstructured":"S\u00f8gaard CK, Nepal A, Petrovic V, Sharma A, Liabakk NB, Steigedal TS, et al. Targeting the non-canonical roles of PCNA modifies and increases the response to targeted anti-cancer therapy. Oncotarget. 2019;10(68):7185\u201397.","journal-title":"Oncotarget"},{"issue":"14","key":"705_CR249","doi-asserted-by":"publisher","first-page":"11752","DOI":"10.18632\/oncotarget.24357","volume":"9","author":"CK S\u00f8gaard","year":"2018","unstructured":"S\u00f8gaard CK, Moestue SA, Rye MB, Kim J, Nepal A, Liabakk NB, et al. APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer. Oncotarget. 2018;9(14):11752\u201366.","journal-title":"Oncotarget"},{"issue":"10","key":"705_CR250","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.chembiol.2023.07.001","volume":"30","author":"L Gu","year":"2023","unstructured":"Gu L, Li M, Li CM, Haratipour P, Lingeman R, Jossart J, et al. Small molecule targeting of transcription-replication conflict for selective chemotherapy. Cell Chem Biol. 2023;30(10):1235-1247.e1236.","journal-title":"Cell Chem Biol"},{"issue":"23","key":"705_CR251","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.1158\/1078-0432.CCR-18-0592","volume":"24","author":"L Gu","year":"2018","unstructured":"Gu L, Lingeman R, Yakushijin F, Sun E, Cui Q, Chao J, et al. The anticancer activity of a first-in-class small-molecule targeting PCNA. Clin Cancer Res. 2018;24(23):6053\u201365.","journal-title":"Clin Cancer Res"},{"key":"705_CR252","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2021.5221","author":"S Lu","year":"2021","unstructured":"Lu S, Dong Z. Proliferating cell nuclear antigen directly interacts with androgen receptor and enhances androgen receptor-mediated signaling. Int J Oncol. 2021. https:\/\/doi.org\/10.3892\/ijo.2021.5221.","journal-title":"Int J Oncol"},{"key":"705_CR253","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.canlet.2021.07.040","volume":"519","author":"X Su","year":"2021","unstructured":"Su X, Wang J, Jiang L, Chen Y, Lu T, Mendonca MS, et al. PCNA inhibition enhances the cytotoxicity of \u03b2-lapachone in NQO1-positive cancer cells by augmentation of oxidative stress-induced DNA damage. Cancer Lett. 2021;519:304\u201314.","journal-title":"Cancer Lett"},{"key":"705_CR254","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jare.2023.02.007","volume":"55","author":"X Dong","year":"2024","unstructured":"Dong X, Lu S, Tian Y, Ma H, Wang Y, Zhang X, et al. Bavachinin protects the liver in NAFLD by promoting regeneration via targeting PCNA. J Adv Res. 2024;55:131\u201344.","journal-title":"J Adv Res"},{"key":"705_CR255","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119504","volume":"277","author":"MJ Ramaiah","year":"2021","unstructured":"Ramaiah MJ, Tangutur AD, Manyam RR. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci. 2021;277:119504.","journal-title":"Life Sci"},{"key":"705_CR256","doi-asserted-by":"publisher","DOI":"10.3390\/nu15183984","author":"Y Wang","year":"2023","unstructured":"Wang Y, Lu L, Ling C, Zhang P, Han R. Potential of dietary HDAC2i in breast cancer patients receiving PD-1\/PD-L1 inhibitors. Nutrients. 2023. https:\/\/doi.org\/10.3390\/nu15183984.","journal-title":"Nutrients"},{"issue":"4","key":"705_CR257","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-20-3305","volume":"27","author":"MD Hellmann","year":"2021","unstructured":"Hellmann MD, J\u00e4nne PA, Opyrchal M, Hafez N, Raez LE, Gabrilovich DI, et al. Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti-PD-(L)1 therapy. Clin Cancer Res. 2021;27(4):1019\u201328.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"705_CR258","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/CMR.0000000000000818","volume":"32","author":"JS Weber","year":"2022","unstructured":"Weber JS, Levinson BA, Laino AS, Pavlick AC, Woods DM. Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III\/IV melanoma. Melanoma Res. 2022;32(5):324\u201333.","journal-title":"Melanoma Res"},{"issue":"2","key":"705_CR259","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","volume":"27","author":"EA Rozeman","year":"2021","unstructured":"Rozeman EA, Hoefsmit EP, Reijers ILM, Saw RPM, Versluis JM, Krijgsman O, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021;27(2):256\u201363.","journal-title":"Nat Med"},{"issue":"4","key":"705_CR260","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/13543776.2020.1725470","volume":"30","author":"C Zhao","year":"2020","unstructured":"Zhao C, Dong H, Xu Q, Zhang Y. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present). Expert Opin Ther Pat. 2020;30(4):263\u201374.","journal-title":"Expert Opin Ther Pat"},{"issue":"1","key":"705_CR261","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12935-023-03051-0","volume":"23","author":"R Han","year":"2023","unstructured":"Han R, Ling C, Wang Y, Lu L. Enhancing HCC treatment: innovatively combining HDAC2 inhibitor with PD-1\/PD-L1 inhibition. Cancer Cell Int. 2023;23(1):203.","journal-title":"Cancer Cell Int"},{"key":"705_CR262","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.578011","volume":"11","author":"L Hontecillas-Prieto","year":"2020","unstructured":"Hontecillas-Prieto L, Flores-Campos R, Silver A, De \u00c1lava E, Hajji N, Garc\u00eda-Dom\u00ednguez DJ. Synergistic enhancement of cancer therapy using HDAC inhibitors: opportunity for clinical trials. Front Genet. 2020;11:578011.","journal-title":"Front Genet"},{"issue":"32","key":"705_CR263","doi-asserted-by":"publisher","first-page":"11774","DOI":"10.1073\/pnas.1410626111","volume":"111","author":"K Kim","year":"2014","unstructured":"Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci. 2014;111(32):11774\u20139.","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"705_CR264","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1158\/2326-6066.CIR-18-0070","volume":"6","author":"BJ Christmas","year":"2018","unstructured":"Christmas BJ, Rafie CI, Hopkins AC, Scott BA, Ma HS, Cruz KA, et al. Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs. Cancer Immunol Res. 2018;6(12):1561\u201377.","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"705_CR265","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","volume":"26","author":"KA Schalper","year":"2020","unstructured":"Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang SP, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med. 2020;26(5):688\u201392.","journal-title":"Nat Med"},{"issue":"1","key":"705_CR266","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-022-00881-4","volume":"29","author":"HC Wang","year":"2022","unstructured":"Wang HC, Haung LY, Wang CJ, Chao YJ, Hou YC, Yen CJ, et al. Tumor-associated macrophages promote resistance of hepatocellular carcinoma cells against sorafenib by activating CXCR2 signaling. J Biomed Sci. 2022;29(1):99.","journal-title":"J Biomed Sci"},{"issue":"1","key":"705_CR267","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01765-9","volume":"9","author":"A Hu","year":"2024","unstructured":"Hu A, Sun L, Lin H, Liao Y, Yang H, Mao Y. Harnessing innate immune pathways for therapeutic advancement in cancer. Signal Transduct Target Ther. 2024;9(1):68.","journal-title":"Signal Transduct Target Ther"},{"key":"705_CR268","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27010137","author":"ZJ Han","year":"2021","unstructured":"Han ZJ, Li YB, Yang LX, Cheng HJ, Liu X, Chen H. Roles of the CXCL8-CXCR1\/2 axis in the tumor microenvironment and immunotherapy. Molecules. 2021. https:\/\/doi.org\/10.3390\/molecules27010137.","journal-title":"Molecules"},{"issue":"20","key":"705_CR269","first-page":"2508","volume":"141","author":"AJ Dunbar","year":"2023","unstructured":"Dunbar AJ, Kim D, Lu M, Farina M, Bowman RL, Yang JL, et al. CXCL8\/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis. Blood. 2023;141(20):2508\u201319.","journal-title":"Blood"},{"issue":"9","key":"705_CR270","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41556-020-0562-4","volume":"22","author":"Y Gao","year":"2020","unstructured":"Gao Y, Nihira NT, Bu X, Chu C, Zhang J, Kolodziejczyk A, et al. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 2020;22(9):1064\u201375.","journal-title":"Nat Cell Biol"},{"issue":"8","key":"705_CR271","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41419-021-04047-2","volume":"12","author":"P Xu","year":"2021","unstructured":"Xu P, Xiong W, Lin Y, Fan L, Pan H, Li Y. Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression. Cell Death Dis. 2021;12(8):779.","journal-title":"Cell Death Dis"},{"issue":"9","key":"705_CR272","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.3390\/ijms22095029","volume":"22","author":"I Bulli","year":"2021","unstructured":"Bulli I, Dettori I, Coppi E, Cherchi F, Venturini M, Di Cesare ML, et al. Role of carbonic anhydrase in cerebral ischemia and carbonic anhydrase inhibitors as putative protective agents. Int J Mol Sci. 2021;22(9):5029.","journal-title":"Int J Mol Sci"},{"key":"705_CR273","doi-asserted-by":"publisher","first-page":"1052657","DOI":"10.3389\/fimmu.2023.1052657","volume":"14","author":"R Han","year":"2023","unstructured":"Han R, Li J, Hony J, Xiao Z, Wang J, Yao M, et al. CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment. Front Immunol. 2023;14:1052657.","journal-title":"Front Immunol"},{"issue":"1","key":"705_CR274","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1080\/14756366.2022.2052868","volume":"37","author":"M Kciuk","year":"2022","unstructured":"Kciuk M, Gieleci\u0144ska A, Mujwar S, Mojzych M, Marciniak B, Drozda R, et al. Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies. J Enzyme Inhib Med Chem. 2022;37(1):1278\u201398.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"5","key":"705_CR275","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1101\/gad.1756509","volume":"23","author":"RG Jones","year":"2009","unstructured":"Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009;23(5):537\u201348.","journal-title":"Genes Dev"},{"key":"705_CR276","unstructured":"Giuntini G. Investigating the Hedgehog pathway and Carbonic Anhydrase XII as prognostic and therapeutic target of melanoma dissemination. 2022."},{"key":"705_CR277","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10555-019-09799-0","volume":"38","author":"S Pastorekova","year":"2019","unstructured":"Pastorekova S, Gillies RJ. The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev. 2019;38:65\u201377.","journal-title":"Cancer Metastasis Rev"},{"key":"705_CR278","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fcell.2016.00027","volume":"4","author":"PC McDonald","year":"2016","unstructured":"McDonald PC, Chafe SC, Dedhar S. Overcoming hypoxia-mediated tumor progression: combinatorial approaches targeting pH regulation, angiogenesis and immune dysfunction. Front Cell Dev Biol. 2016;4:27.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"705_CR279","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s12935-022-02786-6","volume":"22","author":"R Han","year":"2022","unstructured":"Han R, Yang H, Ling C, Lu L. Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor. Cancer Cell Int. 2022;22(1):368.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"705_CR280","doi-asserted-by":"publisher","first-page":"8626","DOI":"10.1038\/s41598-021-88133-7","volume":"11","author":"R Han","year":"2021","unstructured":"Han R, Yang H, Lu L, Lin L. Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs\/Caspase-3 axis. Sci Rep. 2021;11(1):8626.","journal-title":"Sci Rep"},{"issue":"7","key":"705_CR281","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/COC.0000000000000691","volume":"43","author":"PC McDonald","year":"2020","unstructured":"McDonald PC, Chia S, Bedard PL, Chu Q, Lyle M, Tang L, et al. A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors. Am J Clin Oncol. 2020;43(7):484\u201390.","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"705_CR282","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41416-020-01107-w","volume":"124","author":"C Bernauer","year":"2021","unstructured":"Bernauer C, Man YS, Chisholm JC, Lepicard EY, Robinson SP, Shipley JM. Hypoxia and its therapeutic possibilities in paediatric cancers. Br J Cancer. 2021;124(3):539\u201351.","journal-title":"Br J Cancer"},{"issue":"16","key":"705_CR283","doi-asserted-by":"publisher","first-page":"9515","DOI":"10.1200\/JCO.2024.42.16_suppl.9515","volume":"42","author":"RN Amaria","year":"2024","unstructured":"Amaria RN, McQuade JL, Davies MA, Glitza IC, Jose S, Cressman ENK, et al. OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma. J Clin Oncol. 2024;42(16):9515\u20139515.","journal-title":"J Clin Oncol"},{"issue":"4","key":"705_CR284","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","volume":"21","author":"CH Lamers","year":"2013","unstructured":"Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21(4):904\u201312.","journal-title":"Mol Ther"},{"issue":"3","key":"705_CR285","doi-asserted-by":"publisher","first-page":"2276629","DOI":"10.1080\/21645515.2023.2276629","volume":"19","author":"A Jang","year":"2023","unstructured":"Jang A, Lichterman JN, Zhong JY, Shoag JE, Garcia JA, Zhang T, et al. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma. Hum Vaccin Immunother. 2023;19(3):2276629.","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"705_CR286","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/CJI.0000000000000336","volume":"43","author":"I Faiena","year":"2020","unstructured":"Faiena I, Comin-Anduix B, Berent-Maoz B, Bot A, Zomorodian N, Sachdeva A, et al. A phase i, open-label, dose-escalation, and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells transduced with AdGMCA9 (DC-AdGMCAIX) in patients with metastatic renal cell carcinoma. J Immunother. 2020;43(9):273\u201382.","journal-title":"J Immunother"},{"issue":"44","key":"705_CR287","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1038\/onc.2012.550","volume":"32","author":"FE Lock","year":"2013","unstructured":"Lock FE, McDonald PC, Lou Y, Serrano I, Chafe SC, Ostlund C, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene. 2013;32(44):5210\u20139.","journal-title":"Oncogene"},{"issue":"9","key":"705_CR288","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1158\/0008-5472.CAN-10-4261","volume":"71","author":"Y Lou","year":"2011","unstructured":"Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 2011;71(9):3364\u201376.","journal-title":"Cancer Res"},{"key":"705_CR289","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1172\/jci.insight.92928","volume":"2","author":"NH Boyd","year":"2017","unstructured":"Boyd NH, Walker K, Fried J, Hackney JR, McDonald PC, Benavides GA, et al. Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. JCI Insight. 2017;2:24.","journal-title":"JCI Insight"},{"key":"705_CR290","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1172\/JCI153110","volume":"132","author":"WR Ning","year":"2022","unstructured":"Ning WR, Jiang D, Liu XC, Huang YF, Peng ZP, Jiang ZZ, et al. Carbonic anhydrase XII mediates the survival and prometastatic functions of macrophages in human hepatocellular carcinoma. J Clin Invest. 2022;132:7.","journal-title":"J Clin Invest"},{"key":"705_CR291","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cimid.2015.02.001","volume":"39","author":"E Uyangaa","year":"2015","unstructured":"Uyangaa E, Choi JY, Patil AM, Kim JH, Kim SB, Kim K, et al. Functional restoration of exhausted CD4+ and CD8+ T cells in chronic viral infection by vinegar-processed flos of Daphne genkwa. Comp Immunol Microbiol Infect Dis. 2015;39:25\u201337.","journal-title":"Comp Immunol Microbiol Infect Dis"},{"issue":"2","key":"705_CR292","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/10428194.2017.1339875","volume":"59","author":"V Imbert","year":"2018","unstructured":"Imbert V, Nebout M, Mary D, Endou H, Wempe MF, Supuran CT, et al. Co-targeting intracellular pH and essential amino acid uptake cooperates to induce cell death of T-ALL\/LL cells. Leuk Lymphoma. 2018;59(2):460\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"705_CR293","first-page":"505","volume":"15","author":"R Han","year":"2022","unstructured":"Han R, Zhai X, Ling C, Liang S, Lu L. A novel therapeutic strategy of combined CAXII inhibitors and anti\u2013PD-1 antibodies in HCC treatment. Austral Med J. 2022;15(10):505\u20138.","journal-title":"Austral Med J"},{"key":"705_CR294","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms21145001","volume":"21","author":"G M\u00e9hes","year":"2020","unstructured":"M\u00e9hes G, Matolay O, Beke L, Czenke M, P\u00f3rsz\u00e1sz R, Mik\u00f3 E, et al. Carbonic anhydrase inhibitor acetazolamide enhances CHOP treatment response and stimulates effector t-cell infiltration in A20\/BalbC Murine B-cell lymphoma. Int J Mol Sci. 2020;21:14.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"705_CR295","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1158\/1538-7445.AM2016-4740","volume":"76","author":"ML Fishel","year":"2016","unstructured":"Fishel ML, Logsdon DP, Grimard ML, Supuran CT, Zyromski N, Ivan M, et al. Abstract 4740: Targeting Ref-1\/APE1 pathway inhibition in pancreatic cancer using APX3330 for clinical trials. Cancer Res. 2016;76(14):4740\u20134740.","journal-title":"Cancer Res"},{"issue":"10","key":"705_CR296","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1158\/1535-7163.MCT-23-0041","volume":"22","author":"G Venkateswaran","year":"2023","unstructured":"Venkateswaran G, McDonald PC, Chafe SC, Brown WS, Gerbec ZJ, Awrey SJ, et al. A carbonic anhydrase IX\/SLC1A5 axis regulates glutamine metabolism dependent ferroptosis in hypoxic tumor cells. Mol Cancer Ther. 2023;22(10):1228\u201342.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"705_CR297","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.3390\/ijms21124299","volume":"21","author":"A Gibadulinova","year":"2020","unstructured":"Gibadulinova A, Bullova P, Strnad H, Pohlodek K, Jurkovicova D, Takacova M, et al. CAIX-mediated control of LIN28\/let-7 axis contributes to metabolic adaptation of breast cancer cells to hypoxia. Int J Mol Sci. 2020;21(12):4299.","journal-title":"Int J Mol Sci"},{"key":"705_CR298","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.omto.2021.12.019","volume":"24","author":"Y Wang","year":"2022","unstructured":"Wang Y, Buck A, Grimaud M, Culhane AC, Kodangattil S, Razimbaud C, et al. Anti-CAIX BB\u03b6 CAR4\/8 T cells exhibit superior efficacy in a ccRCC mouse model. Mol Ther Oncolytics. 2022;24:385\u201399.","journal-title":"Mol Ther Oncolytics"},{"key":"705_CR299","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.omto.2021.11.018","volume":"24","author":"C Zhang","year":"2022","unstructured":"Zhang C, Fang L, Wang X, Yuan S, Li W, Tian W, et al. Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma. Mol Ther Oncolytics. 2022;24:14\u201325.","journal-title":"Mol Ther Oncolytics"},{"key":"705_CR300","volume-title":"pH-interfering agents as chemosensitizers in cancer therapy","author":"CT Supuran","year":"2020","unstructured":"Supuran CT, Carradori S. pH-interfering agents as chemosensitizers in cancer therapy. London: Academic Press; 2020."},{"issue":"1","key":"705_CR301","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/ijms23010461","volume":"23","author":"S Giovannuzzi","year":"2021","unstructured":"Giovannuzzi S, D\u2019Ambrosio M, Luceri C, Osman SM, Pallecchi M, Bartolucci G, et al. Aromatic sulfonamides including a sulfonic acid tail: new membrane impermeant carbonic anhydrase inhibitors for targeting selectively the cancer-associated isoforms. Int J Mol Sci. 2021;23(1):461.","journal-title":"Int J Mol Sci"},{"issue":"24","key":"705_CR302","doi-asserted-by":"publisher","first-page":"13405","DOI":"10.3390\/ijms222413405","volume":"22","author":"S Kalinin","year":"2021","unstructured":"Kalinin S, Malkova A, Sharonova T, Sharoyko V, Bunev A, Supuran CT, et al. Carbonic anhydrase IX inhibitors as candidates for combination therapy of solid tumors. Int J Mol Sci. 2021;22(24):13405.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"705_CR303","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1158\/2326-6066.CIR-18-0657","volume":"7","author":"SC Chafe","year":"2019","unstructured":"Chafe SC, McDonald PC, Saberi S, Nemirovsky O, Venkateswaran G, Burugu S, et al. Targeting hypoxia-induced carbonic anhydrase IX enhances immune-checkpoint blockade locally and systemically. Cancer Immunol Res. 2019;7(7):1064\u201378.","journal-title":"Cancer Immunol Res"},{"key":"705_CR304","unstructured":"GRAJEK MJ. Mathematical modeling of the tumor microenvironment with the aim of studying its heterogeneity as a driver of treatment resistance and a potential therapy target. Polish Academy Of Sciences; 2023."},{"key":"705_CR305","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fonc.2016.00069","volume":"6","author":"SJ van Kuijk","year":"2016","unstructured":"van Kuijk SJ, Yaromina A, Houben R, Niemans R, Lambin P, Dubois LJ. Prognostic significance of carbonic anhydrase IX expression in cancer patients: a meta-analysis. Front Oncol. 2016;6:69.","journal-title":"Front Oncol"},{"key":"705_CR306","unstructured":"Hynninen P. Expression of Carbonic Anhydrases II, IX and XII in the Normal Female Reproductive Tract, Gynecological Tumors and Lynch Syndrome. 2014."},{"key":"705_CR307","unstructured":"Arneson DL, Arneson W. Therapeutic Drug Monitoring and Toxicology. Clinical Chemistry A Laboratory Perspective.503."},{"issue":"8","key":"705_CR308","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","volume":"17","author":"K Esfahani","year":"2020","unstructured":"Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, et al. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020;17(8):504\u201315.","journal-title":"Nat Rev Clin Oncol"},{"key":"705_CR309","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drudis.2023.103690","volume":"28","author":"L Roy","year":"2023","unstructured":"Roy L, Chatterjee O, Bose D, Roy A, Chatterjee S. Noncoding RNA as an influential epigenetic modulator with promising roles in cancer therapeutics. Drug Discovery Today. 2023;28:9.","journal-title":"Drug Discovery Today"},{"key":"705_CR310","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbcan.2020.188491","volume":"1875","author":"S Toden","year":"2021","unstructured":"Toden S, Zumwalt TJ, Goel A. Non-coding RNAs and potential therapeutic targeting in cancer. Biochimica Et Biophysica Acta-Reviews on Cancer. 2021;1875:1.","journal-title":"Biochimica Et Biophysica Acta-Reviews on Cancer."},{"key":"705_CR311","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fonc.2021.822745","volume":"11","author":"QF Yang","year":"2022","unstructured":"Yang QF, Chen Y, Guo R, Dai YL, Tang LY, Zhao YS, et al. Interaction of ncRNA and epigenetic modifications in gastric cancer: focus on histone modification. Front Oncol. 2022;11:156.","journal-title":"Front Oncol"},{"key":"705_CR312","unstructured":"T G, EZ K, A H, RM G, N H, A S, A D, G H, EB D, S R et al. - RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced."},{"key":"705_CR313","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.2147\/IJN.S461289","volume":"19","author":"R Han","year":"2024","unstructured":"Han R, Rao X, Zhou H, Lu L. Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1\/PD-L1 Inhibition Therapy. Int J Nanomedicine. 2024;19:4803\u201334.","journal-title":"Int J Nanomedicine"},{"key":"705_CR314","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/cancers15030824","volume":"15","author":"H Zhou","year":"2023","unstructured":"Zhou H, Jia W, Lu L, Han R. MicroRNAs with multiple targets of immune checkpoints, as a potential sensitizer for immune checkpoint inhibitors in breast cancer treatment. Cancers (Basel). 2023;15:3.","journal-title":"Cancers (Basel)."},{"issue":"16","key":"705_CR315","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1200\/JCO.2024.42.16_suppl.2539","volume":"42","author":"NT Le","year":"2024","unstructured":"Le NT. A phase I study to evaluate the safety and tolerability of JCXH-211 (a self-replicating mRNA encoding IL-12) intratumoral injection in patients with malignant solid tumors: results from the phase Ia dose escalation. J Clin Oncol. 2024;42(16):2539\u20132539.","journal-title":"J Clin Oncol"},{"key":"705_CR316","unstructured":"J C, H D, B X, H Z, F Z, Z S, J G. - piR-823, a novel non-coding small RNA, demonstrates in vitro and in vivo tumor."},{"key":"705_CR317","unstructured":"R I, M F, T M, H M, M S, D P, J D, M S, O S. - Expression Levels of PIWI-interacting RNA, piR-823, Are Deregulated in Tumor."},{"key":"705_CR318","unstructured":"M Z, D G, Y S, Y W, R J, Q Y, D L, F A, Y Z, H W et al. - miR-149\u20133p reverses CD8(+) T-cell exhaustion by reducing inhibitory receptors and."},{"key":"705_CR319","unstructured":"Promotion BoH, Prevention D, Complementary CotUo, Public AMbtA. Complementary and alternative medicine in the United States. National Academies Press: London 2005."},{"issue":"4","key":"705_CR320","doi-asserted-by":"publisher","DOI":"10.1016\/j.imr.2023.100978","volume":"12","author":"JY Ng","year":"2023","unstructured":"Ng JY, Dhawan T, Fajardo R-G, Masood HA, Sunderji S, Wieland LS, et al. The brief history of complementary, alternative, and integrative medicine terminology and the development and creation of an operational definition. Integrat Med Res. 2023;12(4):100978.","journal-title":"Integrat Med Res"},{"key":"705_CR321","doi-asserted-by":"publisher","DOI":"10.4324\/9781003115984","volume-title":"Holism and complementary medicine: origins and principles","author":"V Di Stefano","year":"2020","unstructured":"Di Stefano V. Holism and complementary medicine: origins and principles. Cham: Routledge; 2020."},{"key":"705_CR322","doi-asserted-by":"publisher","DOI":"10.1016\/j.prmcm.2024.100448","volume":"11","author":"K Singh","year":"2024","unstructured":"Singh K, Gupta JK, Jain D, Kumar S, Singh T, Saha S. Exploring the ancient wisdom and modern relevance of Chinese medicine: a comprehensive review. Pharmacol Res - Modern Chinese Med. 2024;11:100448.","journal-title":"Pharmacol Res - Modern Chinese Med"},{"issue":"3","key":"705_CR323","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.disamonth.2008.12.002","volume":"55","author":"WH Frishman","year":"2009","unstructured":"Frishman WH, Beravol P, Carosella C. Alternative and complementary medicine for preventing and treating cardiovascular disease. Dis Mon. 2009;55(3):121\u201392.","journal-title":"Dis Mon"},{"key":"705_CR324","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.908282","volume":"13","author":"J Li","year":"2022","unstructured":"Li J, Xu D, Liu Y, Cao Y, He J, Liao M. Acupuncture treatment of Guillain-Barr\u00e9 syndrome after using immune checkpoint inhibitors: a case report. Front Neurol. 2022;13:908282.","journal-title":"Front Neurol"},{"issue":"5","key":"705_CR325","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.fct.2006.11.002","volume":"45","author":"Y Shukla","year":"2007","unstructured":"Shukla Y, Singh M. Cancer preventive properties of ginger: a brief review. Food Chem Toxicol. 2007;45(5):683\u201390.","journal-title":"Food Chem Toxicol"},{"key":"705_CR326","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104353","volume":"147","author":"R Shafabakhsh","year":"2019","unstructured":"Shafabakhsh R, Pourhanifeh MH, Mirzaei HR, Sahebkar A, Asemi Z, Mirzaei H. Targeting regulatory T cells by curcumin: a potential for cancer immunotherapy. Pharmacol Res. 2019;147:104353.","journal-title":"Pharmacol Res"},{"issue":"3","key":"705_CR327","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jdermsci.2020.08.001","volume":"99","author":"R Yu","year":"2020","unstructured":"Yu R, Jin L, Li F, Fujimoto M, Wei Q, Lin Z, et al. Dihydroartemisinin inhibits melanoma by regulating CTL\/Treg anti-tumor immunity and STAT3-mediated apoptosis via IL-10 dependent manner. J Dermatol Sci. 2020;99(3):193\u2013202.","journal-title":"J Dermatol Sci"},{"key":"705_CR328","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113705","volume":"155","author":"D Cao","year":"2022","unstructured":"Cao D, Chen D, Xia JN, Wang WY, Zhu GY, Chen LW, et al. Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation. Biomed Pharmacother. 2022;155:113705.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"705_CR329","doi-asserted-by":"publisher","first-page":"152","DOI":"10.33371\/ijoc.v17i2.956","volume":"17","author":"SI Wanandi","year":"2023","unstructured":"Wanandi SI, Maghdalena M. The potency of herbal active compounds as immune modulators for cancer therapy. Indonesian J Cancer. 2023;17(2):152\u201366.","journal-title":"Indonesian J Cancer"},{"key":"705_CR330","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.omto.2020.08.017","volume":"19","author":"R Han","year":"2020","unstructured":"Han R, Nusbaum O, Chen X, Zhu Y. Valeric acid suppresses liver cancer development by acting as a novel HDAC inhibitor. Molecular Therapy - Oncolytics. 2020;19:8\u201318.","journal-title":"Molecular Therapy - Oncolytics"},{"key":"705_CR331","volume-title":"Traditional uses, phytochemistry, and pharmacological activities","author":"KI Wani","year":"2022","unstructured":"Wani KI, Zehra A, Choudhary S, Naeem M, Khan MMA, Khan R, et al. Traditional uses, phytochemistry, and pharmacological activities. Cham: Springer; 2022."},{"key":"705_CR332","doi-asserted-by":"publisher","first-page":"153473542412698","DOI":"10.1177\/15347354241269870","volume":"23","author":"A David","year":"2024","unstructured":"David A, Lev-Ari S. Targeting the gut microbiome to improve immunotherapy outcomes: a review. Integr Cancer Ther. 2024;23:15347354241269870.","journal-title":"Integr Cancer Ther"},{"issue":"3","key":"705_CR333","first-page":"167","volume":"65","author":"W Demark-Wahnefried","year":"2015","unstructured":"Demark-Wahnefried W, Rogers LQ, Alfano CM, Thomson CA, Courneya KS, Meyerhardt JA, et al. Practical clinical interventions for diet, physical activity, and weight control in cancer survivors. CA Cancer J Clin. 2015;65(3):167\u201389.","journal-title":"CA Cancer J Clin"},{"key":"705_CR334","volume-title":"The mediterranean diet: an evidence-based approach","author":"VR Preedy","year":"2020","unstructured":"Preedy VR, Watson RR. The mediterranean diet: an evidence-based approach. London: Academic press; 2020."},{"issue":"1","key":"705_CR335","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell communication and signaling. 2022;20(1):44.","journal-title":"Cell communication and signaling"},{"key":"705_CR336","doi-asserted-by":"publisher","first-page":"1416472","DOI":"10.3389\/fcell.2024.1416472","volume":"12","author":"J Zhao","year":"2024","unstructured":"Zhao J, Jin D, Huang M, Ji J, Xu X, Wang F, et al. Glycolysis in the tumor microenvironment: a driver of cancer progression and a promising therapeutic target. Front Cell Dev Biol. 2024;12:1416472.","journal-title":"Front Cell Dev Biol"},{"key":"705_CR337","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1126\/sciadv.abj0364","volume":"7","author":"SC Chafe","year":"2021","unstructured":"Chafe SC, Vizeacoumar FS, Venkateswaran G, Nemirovsky O, Awrey S, Brown WS, et al. Genome-wide synthetic lethal screen unveils novel CAIX-NFS1\/xCT axis as a targetable vulnerability in hypoxic solid tumors. Sci Adv. 2021;7:35.","journal-title":"Sci Adv"},{"key":"705_CR338","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jconrel.2022.08.031","volume":"350","author":"H Ando","year":"2022","unstructured":"Ando H, Ikeda A, Tagami M, Matsuo NCA, Shimizu T, Ishima Y, et al. Oral administration of sodium bicarbonate can enhance the therapeutic outcome of Doxil\u00ae via neutralizing the acidic tumor microenvironment. J Control Release. 2022;350:414\u201320.","journal-title":"J Control Release"},{"issue":"2","key":"705_CR339","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.cell.2020.11.043","volume":"184","author":"N Wang","year":"2021","unstructured":"Wang N, Jiang X, Zhang S, Zhu A, Yuan Y, Xu H, et al. Structural basis of human monocarboxylate transporter 1 inhibition by anti-cancer drug candidates. Cell. 2021;184(2):370-383.e313.","journal-title":"Cell"},{"issue":"19","key":"705_CR340","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202200152","volume":"61","author":"R Zhao","year":"2022","unstructured":"Zhao R, Fu C, Wang Z, Pan M, Ma B, Yin Q, et al. A pH-responsive nanoparticle library with precise pH tunability by co-polymerization with non-ionizable monomers. Angew Chem Int Ed Engl. 2022;61(19):e202200152.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"3","key":"705_CR341","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2326-6066.CIR-18-0061","volume":"7","author":"HS Ma","year":"2019","unstructured":"Ma HS, Poudel B, Torres ER, Sidhom JW, Robinson TM, Christmas B, et al. A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow t-cell-mediated anticancer activity. Cancer Immunol Res. 2019;7(3):428\u201342.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"705_CR342","first-page":"62","volume":"4","author":"P Gulhati","year":"2023","unstructured":"Gulhati P, Schalck A, Jiang S, Shang X, Wu CJ, Hou P, et al. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1\/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nat Cancer. 2023;4(1):62\u201380.","journal-title":"Nat Cancer"},{"issue":"5","key":"705_CR343","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s41591-025-03512-1","volume":"31","author":"GV Long","year":"2025","unstructured":"Long GV, Shklovskaya E, Satgunaseelan L, Mao Y, da Silva IP, Perry KA, et al. Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma. Nat Med. 2025;31(5):1557\u201366.","journal-title":"Nat Med"},{"issue":"3","key":"705_CR344","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41571-023-00849-9","volume":"21","author":"A Marra","year":"2024","unstructured":"Marra A, Chandarlapaty S, Modi S. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. Nat Rev Clin Oncol. 2024;21(3):185\u2013202.","journal-title":"Nat Rev Clin Oncol"},{"key":"705_CR345","first-page":"29","volume":"1","author":"E Tiberi","year":"2025","unstructured":"Tiberi E, Parisi A, Pistelli M, Savini A, Galassi F, Reschini C, et al. Immunotherapy in triple-negative breast cancer. Oncol Ther. 2025;1:29.","journal-title":"Oncol Ther."},{"issue":"43","key":"705_CR346","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202408598","volume":"11","author":"M Yi","year":"2024","unstructured":"Yi M, Li T, Niu M, Wu Y, Zhao B, Shen Z, et al. Blockade of CCR5(+) T cell accumulation in the tumor microenvironment optimizes anti-TGF-\u03b2\/PD-L1 bispecific antibody. Adv Sci (Weinh). 2024;11(43):e2408598.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"705_CR347","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2051-1426-1-1","volume":"1","author":"I Puzanov","year":"2013","unstructured":"Puzanov I, Milhem M, Andtbacka R, Minor D, Hamid O, Li A, et al. Phase 1 results of a phase 1b\/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma. J Immunother Cancer. 2013;1(1):1\u20132.","journal-title":"J Immunother Cancer"},{"issue":"13","key":"705_CR348","first-page":"036","volume":"79","author":"PS Adusumilli","year":"2019","unstructured":"Adusumilli PS, Zauderer MG, Rusch VW, O\u2019Cearbhaill RE, Zhu A, Ngai DA, et al. Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy. Cancer Res. 2019;79(13):036\u2013036.","journal-title":"Cancer Res"},{"key":"705_CR349","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS9603","volume-title":"Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (NCT# 02965716)","author":"S Hu-Lieskovan","year":"2018","unstructured":"Hu-Lieskovan S, Moon J, Campos D, Grossmann KF, Sosman JA, Ryan CW, et al. Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (NCT# 02965716). American Society of Clinical Oncology; 2018."},{"key":"705_CR350","volume-title":"A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with advanced sarcoma: Results of expansion cohorts","author":"CM Kelly","year":"2023","unstructured":"Kelly CM, Avutu V, Chi P, Dickson MA, Gounder MM, Keohan ML, et al. A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with advanced sarcoma: Results of expansion cohorts. American Society of Clinical Oncology; 2023."},{"key":"705_CR351","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx374.061","volume":"28","author":"K Harrington","year":"2017","unstructured":"Harrington K, Kong A, Mach N, Rordorf T, Corral J, Espeli V, et al. Early safety from phase 1b\/3, multicenter, open-label, randomized trial of talimogene laherparepvec (T-VEC)+ pembrolizumab (pembro) for recurrent or metastatic squamous cell carcinoma of the head and neck (R\/M SCCHN): MASTERKEY-232. Ann Oncol. 2017;28:v394.","journal-title":"Ann Oncol"},{"issue":"4","key":"705_CR352","first-page":"01","volume":"81","author":"VP Nguyen","year":"2021","unstructured":"Nguyen VP, Chang HR, DiNome ML, Oseguera DK, Wong DJ, Nguyen AT, et al. Abstract OT-13\u201301: A phase I study of preoperative ipilimumab, nivolumab, and talimogene laherparepvec for localized breast cancer. Cancer Res. 2021;81(4):01.","journal-title":"Cancer Res"},{"key":"705_CR353","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS10079","volume-title":"Design and rationale of MASTERKEY-115 phase II trial of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in patients with advanced melanoma who progressed on prior anti-programmed cell death-1 (anti-PD-1) therapy","author":"JA Chesney","year":"2020","unstructured":"Chesney JA, Milhem MM, Chaney MF, Gokani P, Snyder W, Robert C. Design and rationale of MASTERKEY-115 phase II trial of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in patients with advanced melanoma who progressed on prior anti-programmed cell death-1 (anti-PD-1) therapy. American Society of Clinical Oncology; 2020."},{"issue":"Suppl 2","key":"705_CR354","first-page":"A396","volume":"9","author":"L Kuryk","year":"2021","unstructured":"Kuryk L, Moller A-S, Kumar S, Shoushtari A, Ares LP, Jaderberg M, et al. 368 Consistent pattern of immune activation induced by oncolytic adenovirus ONCOS-102 across diverse types of solid tumors. J Immunother Cancer. 2021;9(Suppl 2):A396\u2013A396.","journal-title":"J Immunother Cancer"},{"key":"705_CR355","doi-asserted-by":"crossref","unstructured":"Guerrero C, Ensor JE, Sun K, Farach AM, Nair S, Zhang J, Singh M, Darcourt JG, Ramshesh PV, Butler EB. Stereotactic body radiation therapy and in situ oncolytic virus therapy followed by immunotherapy in metastatic non-small cell lung cancer. 2021.","DOI":"10.1200\/JCO.2021.39.15_suppl.9115"},{"key":"705_CR356","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.9541","volume-title":"Efficacy and genetic analysis for a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic immunotherapy, and ipilimumab combination treatment in patients with stage IIIb-IV unresectable or metastatic melanoma","author":"RHI Andtbacka","year":"2018","unstructured":"Andtbacka RHI, Ross MI, Agarwala SS, Taylor MH, Vetto JT, Neves RI, et al. Efficacy and genetic analysis for a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic immunotherapy, and ipilimumab combination treatment in patients with stage IIIb-IV unresectable or metastatic melanoma. American Society of Clinical Oncology; 2018."},{"issue":"3","key":"705_CR357","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/jjco\/hyy170","volume":"49","author":"S Taguchi","year":"2019","unstructured":"Taguchi S, Fukuhara H, Todo T. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives. Jpn J Clin Oncol. 2019;49(3):201\u20139.","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"705_CR358","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00262-022-03314-1","volume":"72","author":"AW Silk","year":"2023","unstructured":"Silk AW, O\u2019Day SJ, Kaufman HL, Bryan J, Norrell JT, Imbergamo C, et al. A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study. Cancer Immunol Immunother. 2023;72(6):1405\u201315.","journal-title":"Cancer Immunol Immunother"},{"key":"705_CR359","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.3014","volume-title":"Activity of a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients previously treated with anti-PD1 blockade therapy","author":"BD Curti","year":"2017","unstructured":"Curti BD, Richards JM, Hallmeyer S, Faries MB, Andtbacka RHI, Daniels GA, et al. Activity of a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients previously treated with anti-PD1 blockade therapy. American Society of Clinical Oncology; 2017."},{"key":"705_CR360","first-page":"8","volume":"1","author":"J Lutzky","year":"2023","unstructured":"Lutzky J, Sullivan RJ, Cohen JV, Ren Y, Li A, Haq R. Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma. J Cancer Res Clin Oncol. 2023;1:8.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"705_CR361","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2020.100639","volume":"45","author":"NH Goradel","year":"2021","unstructured":"Goradel NH, Baker AT, Arashkia A, Ebrahimi N, Ghorghanlu S, Negahdari B. Oncolytic virotherapy: Challenges and solutions. Curr Probl Cancer. 2021;45(1):100639.","journal-title":"Curr Probl Cancer"},{"issue":"2","key":"705_CR362","first-page":"1","volume":"3","author":"H Pandha","year":"2015","unstructured":"Pandha H, Harrington K, Ralph C, Melcher A, Grose M, Shafren D. Phase I\/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients. J Immunother Cancer. 2015;3(2):1\u20131.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"705_CR363","doi-asserted-by":"publisher","first-page":"4668","DOI":"10.1002\/jmv.26947","volume":"93","author":"W Lin","year":"2021","unstructured":"Lin W, Zhao Y, Zhong L. Current strategies of virotherapy in clinical trials for cancer treatment. J Med Virol. 2021;93(8):4668\u201392.","journal-title":"J Med Virol"},{"key":"705_CR364","doi-asserted-by":"publisher","first-page":"S841","DOI":"10.1016\/j.annonc.2021.08.1367","volume":"32","author":"N Kotecki","year":"2021","unstructured":"Kotecki N, Champiat S, Delord J, Vinceneux A, Jungels C, Marabelle A, et al. 983P Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein \u03b1 (SIRP\u03b1) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor. Ann Oncol. 2021;32:S841\u20132.","journal-title":"Ann Oncol"},{"key":"705_CR365","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2019.12.007","volume":"127","author":"W Xu","year":"2020","unstructured":"Xu W, Atkinson VG, Menzies AM. Intratumoural immunotherapies in oncology. Eur J Cancer. 2020;127:1\u201311.","journal-title":"Eur J Cancer"},{"key":"705_CR366","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-40901-1_14","volume-title":"Novel targets in development for advanced renal cell carcinoma","author":"B Thapa","year":"2023","unstructured":"Thapa B, Nelson A, Kilari D. Novel targets in development for advanced renal cell carcinoma. Cham: Springer; 2023."},{"issue":"1","key":"705_CR367","doi-asserted-by":"publisher","first-page":"1984677","DOI":"10.1080\/2162402X.2021.1984677","volume":"10","author":"J Humeau","year":"2021","unstructured":"Humeau J, Le Naour J, Galluzzi L, Kroemer G, Pol JG. Trial watch: intratumoral immunotherapy. OncoImmunology. 2021;10(1):1984677.","journal-title":"OncoImmunology"},{"key":"705_CR368","doi-asserted-by":"publisher","first-page":"S692","DOI":"10.1016\/j.annonc.2024.08.1083","volume":"35","author":"S Champiat","year":"2024","unstructured":"Champiat S, Lebbe C, Baurain J, Italiano A, Sakkal M, Spring-Giusti C, et al. 1024P Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors. Ann Oncol. 2024;35:S692.","journal-title":"Ann Oncol"},{"key":"705_CR369","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fonc.2024.1423143","volume":"14","author":"Z Yuan","year":"2024","unstructured":"Yuan Z, Zhang Y, Wang X, Wang X, Ren S, He X, et al. The investigation of oncolytic viruses in the field of cancer therapy. Front Oncol. 2024;14:56.","journal-title":"Front Oncol"},{"issue":"1","key":"705_CR370","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s41231-023-00144-w","volume":"8","author":"S Thoidingjam","year":"2023","unstructured":"Thoidingjam S, Sriramulu S, Freytag S, Brown SL, Kim JH, Chetty IJ, et al. Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health. Trans Med Commun. 2023;8(1):11.","journal-title":"Trans Med Commun"},{"issue":"6","key":"705_CR371","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1016\/j.ymthe.2024.04.029","volume":"32","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Qian L, Chen K, Gu S, Meng Z, Wang J, et al. Oncolytic adenovirus in treating malignant ascites: a phase II trial and longitudinal single-cell study. Mol Therapy. 2024;32(6):2000.","journal-title":"Mol Therapy"},{"issue":"2","key":"705_CR372","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102239","volume":"9","author":"L Yi","year":"2024","unstructured":"Yi L, Ning Z, Xu L, Shen Y, Zhu X, Yu W, et al. The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study. ESMO open. 2024;9(2):102239.","journal-title":"ESMO open"},{"issue":"10","key":"705_CR373","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.3390\/cancers16101831","volume":"16","author":"P Heumann","year":"2024","unstructured":"Heumann P, Albert A, G\u00fclow K, T\u00fcmen D, M\u00fcller M, Kandulski A. Insights in molecular therapies for hepatocellular carcinoma. Cancers. 2024;16(10):1831.","journal-title":"Cancers"},{"key":"705_CR374","doi-asserted-by":"publisher","first-page":"115627","DOI":"10.1016\/j.biopha.2023.115627","volume":"168","author":"Y Li","year":"2023","unstructured":"Li Y, Duan H-Y, Ye J-f. Advancements and challenges in oncolytic virus therapy for gastrointestinal tumors. Biomed Pharmacotherapy. 2023;168:115627.","journal-title":"Biomed Pharmacotherapy"},{"issue":"7","key":"705_CR375","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1158\/1538-7445.AM2024-CT139","volume":"84","author":"JH Clubb","year":"2024","unstructured":"Clubb JH, Block MS, M\u00e4enp\u00e4\u00e4 J, Pakola S, Haybout L, Quixabeira DC, et al. Abstract CT139: Immunological activity of oncolytic adenovirus encoding TNF\u03b1 and IL-2 (TILT-123) in combination with pembrolizumab in platinum resistant or refractory ovarian cancer patients. Cancer Res. 2024;84(7):139\u2013139.","journal-title":"Cancer Res"},{"key":"705_CR376","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jconrel.2024.09.006","volume":"375","author":"Z Qi","year":"2024","unstructured":"Qi Z, Gu J, Qu L, Shi X, He Z, Sun J, et al. Advancements of engineered live oncolytic biotherapeutics (microbe\/virus\/cells): preclinical research and clinical progress. J Control Release. 2024;375:209\u201335.","journal-title":"J Control Release"},{"key":"705_CR377","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.4_suppl.716","volume-title":"A phase I\/II study combining a TMZ-CD40L\/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel\/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report","author":"BL Musher","year":"2020","unstructured":"Musher BL, Smaglo BG, Abidi W, Othman M, Patel K, Jing J, et al. A phase I\/II study combining a TMZ-CD40L\/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel\/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report. American Society of Clinical Oncology; 2020."},{"issue":"15","key":"705_CR378","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s40265-022-01787-z","volume":"82","author":"S Dhillon","year":"2022","unstructured":"Dhillon S. Pucotenlimab: first approval. Drugs. 2022;82(15):1557\u201364.","journal-title":"Drugs"},{"issue":"4","key":"705_CR379","first-page":"2","volume":"81","author":"K Miller","year":"2021","unstructured":"Miller K, Zhao F, Clark A, Wilkinson G, Laeufle R, Wolff A. Abstract OT-13\u201302: Bracelet-1 (pre0113): a study to assess overall response rate by inducing an inflammatory phenotype in metastatic breast cancer with the oncolytic reovirus pelareorep in combination with anti-PD-L1 avelumab and paclitaxel. Cancer Res. 2021;81(4):2.","journal-title":"Cancer Res"},{"issue":"5","key":"705_CR380","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.3390\/cancers15051404","volume":"15","author":"DK DePalo","year":"2023","unstructured":"DePalo DK, Zager JS. Advances in intralesional therapy for locoregionally advanced and metastatic melanoma: five years of progress. Cancers. 2023;15(5):1404.","journal-title":"Cancers"},{"key":"705_CR381","doi-asserted-by":"crossref","unstructured":"Park JC, Soliman H, Falchook G, Owonikoko T, Spreafico A, Massarelli E, McKean M, Chow L, Ott P, Wesolowski R. 511 Initial results of a phase 1 study of intratumoral ONCR-177, an oncolytic herpes-simplex virus-1 expressing five immunomodulatory transgenes, in subjects with advanced injectable tumors. BMJ Specialist Journals; 2021.","DOI":"10.1136\/jitc-2021-SITC2021.511"},{"key":"705_CR382","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/j.annonc.2023.04.114","volume":"34","author":"E \u00c9lez","year":"2023","unstructured":"\u00c9lez E, Shepard D, Smolenschi C, Bekaii-Saab T, Jac J. P-58 An ongoing open-label, phase 2 trial of RP2 Or RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma. Ann Oncol. 2023;34:S34\u20135.","journal-title":"Ann Oncol"},{"key":"705_CR383","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.trsl.2021.10.006","volume":"240","author":"Y Wang","year":"2022","unstructured":"Wang Y, Jin J, Li Y, Zhou Q, Yao R, Wu Z, et al. NK cell tumor therapy modulated by UV-inactivated oncolytic herpes simplex virus type 2 and checkpoint inhibitors. Transl Res. 2022;240:64\u201386.","journal-title":"Transl Res"},{"issue":"16","key":"705_CR384","doi-asserted-by":"publisher","first-page":"e21537","DOI":"10.1200\/JCO.2022.40.16_suppl.e21537","volume":"40","author":"X Wang","year":"2022","unstructured":"Wang X, Cui C, Lian B, Si L, Chi Z, Sheng X, et al. A phase Ia\/Ib study evaluating the safety and efficacy of intratumorally administrated OH2, an oncolytic herpes simplex virus 2, in unresected stage IIIC to IV melanoma patients. J Clin Oncol. 2022;40(16):e21537\u2013e21537.","journal-title":"J Clin Oncol"},{"key":"705_CR385","doi-asserted-by":"crossref","unstructured":"Shen Y, Qin A, Qiu Y, Jin X, Song W, Fang T, Liang X, Li Y, Tan Q, Zhao R. 766 A clinical trial to evaluate the safety, tolerability and preliminary efficacy of VG161 in combination with Nivolumab in patients with advanced pancreatic cancer. BMJ Specialist Journals; 2023.","DOI":"10.1136\/jitc-2023-SITC2023.0766"},{"key":"705_CR386","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101563","volume":"27","author":"Z Li","year":"2023","unstructured":"Li Z, Feiyue Z, Gaofeng L, Haifeng L. Lung cancer and oncolytic virotherapy\u2013enemy\u2019s enemy. Transl Oncol. 2023;27:101563.","journal-title":"Transl Oncol"},{"issue":"1","key":"705_CR387","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1038\/s41467-021-22929-z","volume":"12","author":"DG Roy","year":"2021","unstructured":"Roy DG, Geoffroy K, Marguerie M, Khan ST, Martin NT, Kmiecik J, et al. Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination. Nat Commun. 2021;12(1):2626.","journal-title":"Nat Commun"},{"issue":"16","key":"705_CR388","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4191","volume":"42","author":"K Kim","year":"2024","unstructured":"Kim K, Saeed A, Sohal D, Edeline J, Heo J, Bhansali A, et al. An open-label, multicenter study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab combined with bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma. J Clin Oncol. 2024;42(16):4191\u20134191.","journal-title":"J Clin Oncol"},{"issue":"16","key":"705_CR389","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS6106","volume":"41","author":"KJ Harrington","year":"2023","unstructured":"Harrington KJ, Cohen E, Zandberg DP, Day TA, Geiger JL, Oliva M, et al. A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2023;41(16):6106\u20136106.","journal-title":"J Clin Oncol"},{"key":"705_CR390","first-page":"1","volume":"12","author":"C Smalley Rumfield","year":"2021","unstructured":"Smalley Rumfield C, Schlom J, Jochems C. Combination therapies for HPV-associated malignancies. J Clin Cell Immunol. 2021;12:1.","journal-title":"J Clin Cell Immunol"},{"issue":"4","key":"705_CR391","first-page":"01","volume":"82","author":"M George","year":"2022","unstructured":"George M, Williams N, Omene C, Chan N, Lu S-E, Tang D, et al. Abstract OT2\u201325\u201301: Irene study: Phase 2 study of Incmga00012 and the oncolytic virus pelareorep in metastatic triple negative breast cancer. Cancer Res. 2022;82(4):01.","journal-title":"Cancer Res"},{"issue":"24","key":"705_CR392","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1158\/1078-0432.CCR-23-0229","volume":"29","author":"ST Nawrocki","year":"2023","unstructured":"Nawrocki ST, Olea J, Villa Celi C, Dadrastoussi H, Wu K, Tsao-Wei D, et al. Comprehensive single-cell immune profiling defines the patient multiple myeloma microenvironment following oncolytic virus therapy in a phase Ib trial. Clin Cancer Res. 2023;29(24):5087\u2013103.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"705_CR393","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/s41416-023-02344-5","volume":"129","author":"D Mahalingam","year":"2023","unstructured":"Mahalingam D, Chen S, Xie P, Loghmani H, Heineman T, Kalyan A, et al. Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC). Br J Cancer. 2023;129(5):782\u201390.","journal-title":"Br J Cancer"},{"issue":"13","key":"705_CR394","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1158\/1538-7445.AM2021-CT191","volume":"81","author":"L Manso","year":"2021","unstructured":"Manso L, Salvador F, Villagrasa P, Chic N, Bermejo B, Cejalvo JM, et al. Abstract CT191: A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (AWARE-1). Cancer Res. 2021;81(13):191\u2013191.","journal-title":"Cancer Res"},{"issue":"21","key":"705_CR395","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.3390\/cancers15215291","volume":"15","author":"Z Wang","year":"2023","unstructured":"Wang Z, Sun P, Li Z, Xiao S. Clinical advances and future directions of oncolytic virotherapy for head and neck cancer. Cancers. 2023;15(21):5291.","journal-title":"Cancers"},{"key":"705_CR396","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1182\/blood-2018-99-113500","volume":"132","author":"CC Hofmeister","year":"2018","unstructured":"Hofmeister CC, Sborov DW, Viola D, Dona A, Nuovo GJ, Benson DM Jr, et al. Oncolytics virus replication using pelareorep (Reolysin) and carfilzomib in relapsed myeloma patients increases PD-L1 expression with clinical responses. Blood. 2018;132:2655.","journal-title":"Blood"},{"issue":"19","key":"705_CR397","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.3390\/cancers14194701","volume":"14","author":"B Oronsky","year":"2022","unstructured":"Oronsky B, Gastman B, Conley AP, Reid C, Caroen S, Reid T. Oncolytic adenoviruses: the cold war against cancer finally turns hot. Cancers. 2022;14(19):4701.","journal-title":"Cancers"},{"issue":"6","key":"705_CR398","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1093\/neuonc\/noab271","volume":"24","author":"EA Chiocca","year":"2022","unstructured":"Chiocca EA, Gelb AB, Chen CC, Rao G, Reardon DA, Wen PY, et al. Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: an open-label, multi-institutional phase I trial. Neuro Oncol. 2022;24(6):951\u201363.","journal-title":"Neuro Oncol"},{"issue":"9","key":"705_CR399","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1080\/14737175.2024.2376847","volume":"24","author":"MJ Goldman","year":"2024","unstructured":"Goldman MJ, Baskin AM, Sharpe MA, Baskin DS. Advances in gene therapy for high-grade glioma: a review of the clinical evidence. Expert Rev Neurother. 2024;24(9):879\u201395.","journal-title":"Expert Rev Neurother"},{"issue":"16","key":"705_CR400","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1158\/1538-7445.AM2020-CT244","volume":"80","author":"GK Dy","year":"2020","unstructured":"Dy GK, Davar D, Galanis E, Townsley D, Karanovic D, Schwaederle M, et al. Abstract CT244: A phase 1 study of IV MEDI5395, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors. Cancer Res. 2020;80(16):244\u2013244.","journal-title":"Cancer Res"},{"key":"705_CR401","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/annonc\/mdz451.036","volume":"30","author":"M Jove","year":"2019","unstructured":"Jove M, Bra\u00f1a I, Taberna M, Hernando-Calvo A, Castro JB, Garralda E, et al. 128TiP VCN-01 plus durvalumab in subjects with recurrent\/metastatic head & neck squamous cell carcinoma (R\/M HNSCC): Phase I clinical trial. Ann Oncol. 2019;30:47.","journal-title":"Ann Oncol"},{"issue":"3","key":"705_CR402","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS602","volume":"42","author":"PW McGarrah","year":"2024","unstructured":"McGarrah PW, Naik S, Halfdanarson TR, Peng KW, Russell SJ, Molina JR, et al. Phase 1\/2 trial of vesicular stomatitis virus expressing human interferon-\u03b2 and NIS (VSV-IFN\u03b2-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma. J Clin Oncol. 2024;42(3):602\u2013602.","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"705_CR403","first-page":"A1005","volume":"9","author":"R Li","year":"2021","unstructured":"Li R, Steinberg G, Lamm D, Uchio E, Packiam V, Kamat A, et al. 955 CORE1: phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG). J Immunother Cancer. 2021;9(Suppl 2):A1005\u2013A1005.","journal-title":"J Immunother Cancer"},{"key":"705_CR404","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS2705","volume-title":"An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumors","author":"KJ Harrington","year":"2022","unstructured":"Harrington KJ, Rullan A, Deighton L, Barata J, Castro H, Ahlers CM, et al. An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumors. In.: American Society of Clinical Oncology; 2022."},{"issue":"1","key":"705_CR405","doi-asserted-by":"publisher","first-page":"2290900","DOI":"10.1080\/2162402X.2023.2290900","volume":"13","author":"M Nielsen","year":"2024","unstructured":"Nielsen M, Monberg T, Sundvold V, Albieri B, Hovgaard D, Petersen MM, et al. LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma. Oncoimmunology. 2024;13(1):2290900.","journal-title":"Oncoimmunology"},{"key":"705_CR406","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS2671","volume-title":"An open label, multicenter, phase I\/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors","author":"MR Middleton","year":"2019","unstructured":"Middleton MR, Sacco JJ, Merchan JR, Curti BD, Vanderwalde AM, Olsson-Brown AC, et al. An open label, multicenter, phase I\/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors. In.: American Society of Clinical Oncology; 2019."},{"key":"705_CR407","doi-asserted-by":"publisher","first-page":"S904","DOI":"10.1016\/j.annonc.2021.08.1479","volume":"32","author":"A Haydon","year":"2021","unstructured":"Haydon A, Alamgeer M, Brungs D, Collichio F, Khushalani N, Colevas A, et al. 1094TiP A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]. Ann Oncol. 2021;32:S904.","journal-title":"Ann Oncol"},{"key":"705_CR408","doi-asserted-by":"publisher","first-page":"S1180","DOI":"10.1016\/j.annonc.2023.09.1335","volume":"34","author":"B Janji","year":"2023","unstructured":"Janji B, Noman MZ, Hossain J, Prestegarden L, Pico-Navarro C, Rigg E, et al. 2308P CyPep-1 reprograms the tumor microenvironment and enhances the efficacy of immune checkpoint inhibitors. Ann Oncol. 2023;34:S1180.","journal-title":"Ann Oncol"},{"key":"705_CR409","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113347","volume":"194","author":"E Zappa","year":"2023","unstructured":"Zappa E, Vitali A, Anders K, Molenaar JJ, Wienke J, K\u00fcnkele A. Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges. Eur J Cancer. 2023;194:113347.","journal-title":"Eur J Cancer"},{"key":"705_CR410","doi-asserted-by":"crossref","unstructured":"Bagley SJ, Binder ZA, Desai AS, Nasrallah MP, Maloney E, Brem S, Lustig R, Kurtz G, Alonso-Basanta M, Mohan S. Phase I study of repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab in patients with newly diagnosed, MGMT-unmethylated glioblastoma. 2023.","DOI":"10.21203\/rs.3.rs-2742648\/v1"},{"key":"705_CR411","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy485.002","volume":"29","author":"S Chen","year":"2018","unstructured":"Chen S, Lin Y, Zhong S, An H, Lu Y, Yin M, et al. Anti-MUC1 CAR-T cells combined with PD-1 knockout engineered T cells for patients with non-small cell lung cancer (NSCLC): A pilot study. Ann Oncol. 2018;29:x11.","journal-title":"Ann Oncol"},{"key":"705_CR412","doi-asserted-by":"crossref","unstructured":"Botta GP, Becerra CR, Jin Z, Kim DW, Zhao D, Lenz H-J, Ma H, Ween A, Acha P, Li Z. Multicenter phase Ib trial in the US of salvage CT041 CLDN18. 2-specific chimeric antigen receptor T-cell therapy for patients with advanced gastric and pancreatic adenocarcinoma. Am Soc Clin Oncol. 2022.","DOI":"10.1200\/JCO.2022.40.16_suppl.2538"},{"issue":"7","key":"705_CR413","doi-asserted-by":"publisher","first-page":"6482","DOI":"10.1158\/1538-7445.AM2023-6482","volume":"83","author":"C XiaoYi","year":"2023","unstructured":"XiaoYi C, Qi C, Gong J, Zhang M, Ma M. CLDN18 2 expression is associated with clinicopathological features and prognosis of Chinese patients with digestive system cancers: a retrospective analysis. Cancer Res. 2023;83(7):6482\u20136482.","journal-title":"Cancer Res"},{"key":"705_CR414","doi-asserted-by":"publisher","first-page":"1290488","DOI":"10.3389\/fimmu.2023.1290488","volume":"14","author":"IS Ciulean","year":"2023","unstructured":"Ciulean IS, Fischer J, Quaiser A, Bach C, Abken H, Tretbar US, et al. CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma. Front Immunol. 2023;14:1290488.","journal-title":"Front Immunol"},{"key":"705_CR415","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.hoc.2023.05.009","volume":"37","author":"JA Wala","year":"2023","unstructured":"Wala JA, Hanna GJ. Chimeric antigen receptor t-cell therapy for solid. Car T-Cell, an Issue of Hematology\/Oncology Clinics of North America, E-Book. 2023;37:1149.","journal-title":"Car T-Cell, an Issue of Hematology\/Oncology Clinics of North America, E-Book"},{"key":"705_CR416","first-page":"10","volume":"1","author":"J Force","year":"2017","unstructured":"Force J, Salama AK. First-line treatment of metastatic melanoma: role of nivolumab. ImmunoTargets Therapy. 2017;1:10.","journal-title":"ImmunoTargets Therapy"},{"key":"705_CR417","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-819840-7.00004-2","volume-title":"The use of immunotherapy for treatment of chemoresistant ovarian cancer","author":"AF Agyemang","year":"2021","unstructured":"Agyemang AF, Odunsi KO. The use of immunotherapy for treatment of chemoresistant ovarian cancer. Amsterdam: Elsevier; 2021."},{"key":"705_CR418","doi-asserted-by":"crossref","unstructured":"Olson DJ, Larkin J, Hong Y, Thomas S, Martin-Liberal J, Furness AJ, Terheyden P, Poklepovic AS, Samhouri Y, Lammers P. 778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-na\u00efve unresectable or metastatic melanoma. BMJ Specialist Journals; 2023.","DOI":"10.1136\/jitc-2023-SITC2023.0778"},{"issue":"3","key":"705_CR419","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40291-024-00708-y","volume":"28","author":"SJ Keam","year":"2024","unstructured":"Keam SJ. Lifileucel: first approval. Mol Diagn Ther. 2024;28(3):339\u201344.","journal-title":"Mol Diagn Ther"},{"key":"705_CR420","doi-asserted-by":"publisher","first-page":"1018962","DOI":"10.3389\/fimmu.2022.1018962","volume":"13","author":"MH Kazemi","year":"2022","unstructured":"Kazemi MH, Sadri M, Najafi A, Rahimi A, Baghernejadan Z, Khorramdelazad H, et al. Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango? Front Immunol. 2022;13:1018962.","journal-title":"Front Immunol"},{"key":"705_CR421","doi-asserted-by":"crossref","unstructured":"Gettinger S, Kluger H, Schoenfeld A, Betof-Warner A, He K, Sukari A, Doger de Speville Uribe B, Lee S, Haefliger S, Goldberg Z. Abstract CT235: A Phase 2, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144\/LN-145\/LN-145-S1) in patients with solid tumors. Cancer Research. 2021; 81(13):235-235.","DOI":"10.1158\/1538-7445.AM2021-CT235"},{"key":"705_CR422","doi-asserted-by":"crossref","unstructured":"O\u2019Malley D, Lee S, Psyrri A, Sukari A, Thomas S, Wenham R, Gogas H, Jazaeri A, Monk B, Rose P. 492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-na\u00efve patients with advanced cancers. BMJ Specialist Journals; 2021.","DOI":"10.1136\/jitc-2021-SITC2021.492"},{"key":"705_CR423","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.9543","volume-title":"Lymphodepletion (LD), tumor-infiltrating lymphocytes (TIL) and high (HD-IL2) versus low-dose (LD-IL2) IL-2 followed by pembrolizumab (pembro) in patients (pts) with metastatic melanoma (MM)","author":"RN Amaria","year":"2019","unstructured":"Amaria RN, Haymaker CL, Forget M-A, Bassett R, Cormier JN, Davies MA, et al. Lymphodepletion (LD), tumor-infiltrating lymphocytes (TIL) and high (HD-IL2) versus low-dose (LD-IL2) IL-2 followed by pembrolizumab (pembro) in patients (pts) with metastatic melanoma (MM). .: American Society of Clinical Oncology; 2019."},{"issue":"5","key":"705_CR424","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28344","volume":"3","author":"F Aranda","year":"2014","unstructured":"Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Herv\u00e9 Fridman W, et al. Trial Watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology. 2014;3(5):e28344.","journal-title":"Oncoimmunology"},{"issue":"1","key":"705_CR425","first-page":"5618174","volume":"2017","author":"C Zichi","year":"2017","unstructured":"Zichi C, Tucci M, Leone G, Buttigliero C, Vignani F, Pignataro D, et al. Immunotherapy for patients with advanced urothelial cancer: current evidence and future perspectives. Biomed Res Int. 2017;2017(1):5618174.","journal-title":"Biomed Res Int"},{"issue":"2","key":"705_CR426","doi-asserted-by":"publisher","first-page":"296","DOI":"10.37349\/etat.2024.00219","volume":"5","author":"JM Verner","year":"2024","unstructured":"Verner JM, Arbuthnott HF, Ramachandran R, Bharadwaj M, Chaudhury N, Jou E. Emerging roles of type 1 innate lymphoid cells in tumour pathogenesis and cancer immunotherapy. Expl Target Anti-tumor Therapy. 2024;5(2):296.","journal-title":"Expl Target Anti-tumor Therapy"},{"issue":"10","key":"705_CR427","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s11912-023-01443-z","volume":"25","author":"M Imbimbo","year":"2023","unstructured":"Imbimbo M, Wetterwald L, Friedlaender A, Parikh K, Addeo A. Cellular therapy in NSCLC: between myth and reality. Curr Oncol Rep. 2023;25(10):1161\u201374.","journal-title":"Curr Oncol Rep"},{"key":"705_CR428","doi-asserted-by":"crossref","unstructured":"Amaria RN, Bernatchez C, Forget M-A, Haymaker CL, Conley AP, Livingston JA, Varadhachary GR, Javle MM, Maitra A, Tzeng C-WD. Adoptive transfer of tumor-infiltrating lymphocytes in patients with sarcomas, ovarian, and pancreatic cancers. 2019.","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS2650"},{"issue":"19","key":"705_CR429","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.3390\/cancers15194814","volume":"15","author":"L Davis","year":"2023","unstructured":"Davis L, Miller RE, Wong YNS. The landscape of adoptive cellular therapies in ovarian cancer. Cancers. 2023;15(19):4814.","journal-title":"Cancers"},{"key":"705_CR430","first-page":"56","volume":"16","author":"D Dangaj","year":"2022","unstructured":"Dangaj D, Barras D, Ghisoni E, Chiffelle J, Orcurto A, Dagher J, et al. 5P Tumor microenvironment cellular crosstalk predicts response to adoptive TIL therapy in melanoma patients. Immuno-Oncol Technol. 2022;16:56.","journal-title":"Immuno-Oncol Technol"},{"issue":"1","key":"705_CR431","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12943-022-01688-5","volume":"21","author":"R Qu","year":"2022","unstructured":"Qu R, Kluger Y, Yang J, Zhao J, Hafler DA, Krause DS, et al. Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure. Mol Cancer. 2022;21(1):219.","journal-title":"Mol Cancer"},{"key":"705_CR432","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3107","volume-title":"A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (TIL, LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC","author":"SM Lee","year":"2018","unstructured":"Lee SM, Haigentz M, Villaruz LC, Gorbatchevsky I, Suzuki S, Tanamly S, et al. A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (TIL, LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC. American Society of Clinical Oncology; 2018."},{"issue":"16","key":"705_CR433","first-page":"056","volume":"80","author":"B Creelan","year":"2020","unstructured":"Creelan B, Wang C, Teer J, Toloza E, Mullinax J, Yao J, et al. Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): a phase I trial. Cancer Res. 2020;80(16):056\u2013056.","journal-title":"Cancer Res"},{"issue":"2","key":"705_CR434","doi-asserted-by":"publisher","DOI":"10.4161\/onci.27297","volume":"3","author":"F Aranda","year":"2014","unstructured":"Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, et al. Trial Watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology. 2014;3(2):e27297.","journal-title":"Oncoimmunology"},{"issue":"4","key":"705_CR435","first-page":"274","volume":"21","author":"X Li","year":"2024","unstructured":"Li X, You J, Hong L, Liu W, Guo P, Hao X. Neoantigen cancer vaccines: a new star on the horizon. Cancer Biol Med. 2024;21(4):274.","journal-title":"Cancer Biol Med"},{"issue":"7","key":"705_CR436","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.21037\/tcr-24-196","volume":"13","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhang X, Chen G, Shao M. Clinical research progress of telomerase targeted cancer immunotherapy: a literature review. Transl Cancer Res. 2024;13(7):3904.","journal-title":"Transl Cancer Res"},{"issue":"1","key":"705_CR437","first-page":"53","volume":"22","author":"S Sato","year":"2023","unstructured":"Sato S, Nakamura Y, Oki E, Yoshino T. Molecular residual disease-guided adjuvant treatment in resected colorectal cancer: focus on CIRCULATE-Japan. Clin Colorectal Cancer. 2023;22(1):53\u20138.","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"705_CR438","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00262-020-02729-y","volume":"70","author":"KL Lee","year":"2021","unstructured":"Lee KL, Schlom J, Hamilton DH. Combination therapies utilizing neoepitope-targeted vaccines. Cancer Immunol Immunother. 2021;70(4):875\u201385.","journal-title":"Cancer Immunol Immunother"},{"issue":"16","key":"705_CR439","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3635","volume":"40","author":"JR Hecht","year":"2022","unstructured":"Hecht JR, Shergill A, Goldstein MG, Fang B, Cho MT, Lenz H-J, et al. Phase 2\/3, randomized, open-label study of an individualized neoantigen vaccine (self-amplifying mRNA and adenoviral vectors) plus immune checkpoint blockade as maintenance for patients with newly diagnosed metastatic colorectal cancer (GRANITE). J Clin Oncol. 2022;40(16):3635\u20133635.","journal-title":"J Clin Oncol"},{"issue":"3","key":"705_CR440","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3390\/vaccines11030634","volume":"11","author":"K Devaraja","year":"2023","unstructured":"Devaraja K, Aggarwal S, Singh M. Therapeutic vaccination in head and neck squamous cell carcinoma\u2014a review. Vaccines. 2023;11(3):634.","journal-title":"Vaccines"},{"key":"705_CR441","first-page":"141","volume":"108","author":"A G\u00fcl","year":"2021","unstructured":"G\u00fcl A, Erkunt-Alak S, G\u00fcl C, Karakavuk T, Can H, Karakavuk M. Breast cancer vaccines: current status and future approach. Front Clin Drug Res-Anti-Cancer Agents Bentham Books imprint. 2021;108:141.","journal-title":"Front Clin Drug Res-Anti-Cancer Agents Bentham Books imprint"},{"issue":"12","key":"705_CR442","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1080\/13543784.2022.2160313","volume":"31","author":"R Cioffi","year":"2022","unstructured":"Cioffi R, Galli F, Rabaiotti E, Candiani M, Pella F, Candotti G, et al. Experimental drugs for fallopian cancer: promising agents in the clinical trials and key stumbling blocks for researchers. Expert Opin Investig Drugs. 2022;31(12):1339\u201357.","journal-title":"Expert Opin Investig Drugs"},{"key":"705_CR443","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106520","volume":"145","author":"N Ngamphaiboon","year":"2023","unstructured":"Ngamphaiboon N, Chairoungdua A, Dajsakdipon T, Jiarpinitnun C. Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo) radiotherapy of locally advanced head and neck squamous cell carcinoma. Oral Oncol. 2023;145:106520.","journal-title":"Oral Oncol"},{"issue":"16","key":"705_CR444","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1182\/bloodadvances.2023009903","volume":"7","author":"JA Waksal","year":"2023","unstructured":"Waksal JA, Bruedigam C, Komrokji RS, Jamieson CH, Mascarenhas JO. Telomerase-targeted therapies in myeloid malignancies. Blood Adv. 2023;7(16):4302\u201314.","journal-title":"Blood Adv"},{"issue":"8","key":"705_CR445","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/14740338.2021.1915281","volume":"20","author":"SK Cimino","year":"2021","unstructured":"Cimino SK, Ciombor KK, Chakravarthy AB, Bailey CE, Hopkins MB, Geiger TM, et al. Safety considerations with new treatment regimens for anal cancer. Expert Opin Drug Saf. 2021;20(8):889\u2013902.","journal-title":"Expert Opin Drug Saf"},{"key":"705_CR446","first-page":"134","volume":"121","author":"R Imperial","year":"2024","unstructured":"Imperial R, Mosalem O, Majeed U, Tran NH, Borad MJ, Babiker H. Second-line treatment of pancreatic adenocarcinoma: shedding light on new opportunities and key talking points from clinical trials. Clin Exper Gastroenterol. 2024;121:134.","journal-title":"Clin Exper Gastroenterol"},{"issue":"9","key":"705_CR447","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70020","volume":"14","author":"A Alsalloum","year":"2024","unstructured":"Alsalloum A, Shevchenko JA, Sennikov S. NY-ESO-1 antigen: a promising frontier in cancer immunotherapy. Clin Transl Med. 2024;14(9):e70020.","journal-title":"Clin Transl Med"},{"key":"705_CR448","first-page":"56","volume":"9","author":"M Offin","year":"2023","unstructured":"Offin M, Fitzgerald B, Zauderer MG, Doroshow D. The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas. J Cancer Metastasis Treat. 2023;9:56.","journal-title":"J Cancer Metastasis Treat"},{"key":"705_CR449","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/annonc\/mdz451.002","volume":"30","author":"M Johnson","year":"2019","unstructured":"Johnson M, Spira A, Carbone D, Drake C, Henick B, Ingham M, et al. First results of phase I\/II studies evaluating viral vector-based heterologous prime\/boost immunotherapy against predicted HLA class I neoantigens demonstrate CD8 T cell responses in patients with advanced cancers. Ann Oncol. 2019;30:34.","journal-title":"Ann Oncol"},{"key":"705_CR450","doi-asserted-by":"publisher","first-page":"S1288","DOI":"10.1016\/j.annonc.2023.10.043","volume":"34","author":"J Weber","year":"2023","unstructured":"Weber J, Khattak A, Carlino M, Sullivan R, Luke J, Meniawy T, et al. LBA49 mRNA-4157 (V940) individualized neoantigen therapy+ pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response. Ann Oncol. 2023;34:S1288\u20139.","journal-title":"Ann Oncol"},{"issue":"7963","key":"705_CR451","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144\u201350.","journal-title":"Nature"},{"issue":"11","key":"705_CR452","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen A, Haanen JBAG, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023;29(11):2844\u201353.","journal-title":"Nat Med"},{"issue":"1","key":"705_CR453","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41392-024-01824-1","volume":"9","author":"R Fu","year":"2024","unstructured":"Fu R, Qi R, Xiong H, Lei X, Jiang Y, He J, et al. Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects. Signal Transduct Target Ther. 2024;9(1):118.","journal-title":"Signal Transduct Target Ther"},{"issue":"15","key":"705_CR454","doi-asserted-by":"publisher","first-page":"9567","DOI":"10.1200\/JCO.2020.38.15_suppl.9567","volume":"38","author":"AN Saltos","year":"2020","unstructured":"Saltos AN, Tanvetyanon T, Creelan BC, Shafique MR, Antonia SJ, Haura EB, et al. Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC). J Clin Oncol. 2020;38(15):9567\u20139567.","journal-title":"J Clin Oncol"},{"issue":"16","key":"705_CR455","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1200\/JCO.2023.41.16_suppl.2597","volume":"41","author":"CL Tourneau","year":"2023","unstructured":"Tourneau CL, Bigot F, Vansteene D, Kamal M, Ghiringhelli F, Mazzarella L, et al. Phase II basket trial evaluating the efficacy of pembrolizumab (PE) combined with vorinostat (VO) in patients (pts) with recurrent and\/or metastatic squamous cell carcinoma (SCC). J Clin Oncol. 2023;41(16):2597\u20132597.","journal-title":"J Clin Oncol"},{"issue":"15","key":"705_CR456","doi-asserted-by":"publisher","first-page":"10052","DOI":"10.1200\/JCO.2020.38.15_suppl.10052","volume":"38","author":"JS Weber","year":"2020","unstructured":"Weber JS, Laino AS, Vassallo M, Pavlick A, Malatyali S, Krishnarajapet S, et al. Preclinical and clinical studies of a class I\/IV HDAC inhibitor, mocetinostat, in melanoma. J Clin Oncol. 2020;38(15):10052\u201310052.","journal-title":"J Clin Oncol"},{"issue":"7","key":"705_CR457","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1320","volume":"13","author":"Z Fu","year":"2023","unstructured":"Fu Z, Zhang X, Gao Y, Fan J, Gao Q. Enhancing the anticancer immune response with the assistance of drug repurposing and delivery systems. Clin Transl Med. 2023;13(7):e1320.","journal-title":"Clin Transl Med"},{"issue":"12","key":"705_CR458","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.3390\/v14122796","volume":"14","author":"Y Wu","year":"2022","unstructured":"Wu Y, Chen X, Wang L, Zhou X, Liu Y, Ji D, et al. Histone deacetylase inhibitor panobinostat benefits the therapeutic efficacy of oncolytic herpes simplex virus combined with PD-1\/PD-L1 blocking in glioma and squamous cell carcinoma models. Viruses. 2022;14(12):2796.","journal-title":"Viruses"},{"key":"705_CR459","doi-asserted-by":"publisher","first-page":"S1315","DOI":"10.1016\/j.annonc.2021.08.2117","volume":"32","author":"C Blank","year":"2021","unstructured":"Blank C, Reijers I, Versluis J, Menzies A, Dimitriadis P, Wouters M, et al. LBA39 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-\u03b3 sign): The DONIMI study. Ann Oncol. 2021;32:S1315.","journal-title":"Ann Oncol"},{"issue":"5","key":"705_CR460","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221952","volume":"220","author":"IL Reijers","year":"2023","unstructured":"Reijers IL, Rao D, Versluis JM, Menzies AM, Dimitriadis P, Wouters MW, et al. IFN-\u03b3 signature enables selection of neoadjuvant treatment in patients with stage III melanoma. J Exp Med. 2023;220(5):e20221952.","journal-title":"J Exp Med"},{"issue":"4","key":"705_CR461","first-page":"06","volume":"80","author":"ETR Torres","year":"2020","unstructured":"Torres ETR, Kagohara LT, Davis E, Rafie C, Christmas B, Zhu Q, et al. Abstract P5\u201304\u201306: Reprogramming the suppressive tumor microenvironment of breast cancer. Cancer Res. 2020;80(4):06.","journal-title":"Cancer Res"},{"key":"705_CR462","doi-asserted-by":"publisher","first-page":"6157","DOI":"10.3390\/cancers13246157","volume":"13","author":"M Maucher","year":"2021","unstructured":"Maucher M, Srour M, Danhof S, Einsele H, Hudecek M, Yakoub-Agha I. Current limitations and perspectives of chimeric antigen receptor-t-cells in acute myeloid leukemia. Cancers. 2021;13:6157.","journal-title":"Cancers"},{"issue":"18","key":"705_CR463","doi-asserted-by":"publisher","first-page":"10677","DOI":"10.3390\/ijms231810677","volume":"23","author":"J-S Chen","year":"2022","unstructured":"Chen J-S, Hsieh Y-C, Chou C-H, Wu Y-H, Yang M-H, Chu S-H, et al. Chidamide plus tyrosine kinase inhibitor remodel the tumor immune microenvironment and reduce tumor progression when combined with immune checkpoint inhibitor in na\u00efve and anti-PD-1 resistant CT26-bearing mice. Int J Mol Sci. 2022;23(18):10677.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"705_CR464","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.7150\/jca.44622","volume":"11","author":"YD Kim","year":"2020","unstructured":"Kim YD, Park SM, Ha HC, Lee AR, Won H, Cha H, et al. HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment. J Cancer. 2020;11(14):4059\u201372.","journal-title":"J Cancer"},{"issue":"49","key":"705_CR465","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1038\/onc.2015.46","volume":"34","author":"K Cao","year":"2015","unstructured":"Cao K, Wang G, Li W, Zhang L, Wang R, Huang Y, et al. Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity. Oncogene. 2015;34(49):5960\u201370.","journal-title":"Oncogene"},{"key":"705_CR466","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS9599","volume-title":"A phase 1\/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors","author":"AJ Schoenfeld","year":"2024","unstructured":"Schoenfeld AJ, Betof Warner A, Chesney JA, Thomas SS, Hamid O, In GK, et al. A phase 1\/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors. American Society of Clinical Oncology; 2024."},{"issue":"3","key":"705_CR467","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3233\/KCA-220001","volume":"6","author":"Y Lyou","year":"2022","unstructured":"Lyou Y, Dorff TB. Chimeric antigen receptor (CAR) T-cell treatment in renal cell carcinoma: current clinical trials and future directions. Kidney Cancer. 2022;6(3):159\u201368.","journal-title":"Kidney Cancer"},{"issue":"9","key":"705_CR468","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41422-024-00990-9","volume":"34","author":"X Wang","year":"2024","unstructured":"Wang X, Wang W, Zou S, Xu Z, Cao D, Zhang S, et al. Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in patients with advanced solid tumors. Cell Res. 2024;34(9):661\u20134.","journal-title":"Cell Res"},{"issue":"16","key":"705_CR469","doi-asserted-by":"publisher","first-page":"e14583","DOI":"10.1200\/JCO.2024.42.16_suppl.e14583","volume":"42","author":"N Li","year":"2024","unstructured":"Li N, Li N, Wang Y, Cui N, Wang X, Tang Y, et al. Preliminary safety, antitumor activity, and pharmacodynamics of intratumoral ABO2011 (IL-12 mRNA) in patients with advanced solid tumors. J Clin Oncol. 2024;42(16):e14583\u2013e14583.","journal-title":"J Clin Oncol"},{"key":"705_CR470","first-page":"56","volume":"31","author":"C Fulgenzi","year":"2022","unstructured":"Fulgenzi C, D\u2019Alessio A, Ogunbiyi O, Demirta\u015f C, Gennari A, Cortellini A, et al. Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: Will they shape the future treatment landscape? Expert Opin Investigat Drugs. 2022;31:56.","journal-title":"Expert Opin Investigat Drugs."},{"issue":"8","key":"705_CR471","first-page":"92","volume":"83","author":"R Plummer","year":"2023","unstructured":"Plummer R, Sodergren M, Ryan B, Tchakov I, Raulf N, Hodgson R, et al. Abstract LB192: MTL-CEBPA in combination with pembrolizumab converts an immune desert to an inflamed TME in solid tumors resistant to checkpoint blockade. Cancer Res. 2023;83(8):92\u2013192.","journal-title":"Cancer Res"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00705-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00705-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00705-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T19:03:23Z","timestamp":1760555003000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00705-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":471,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["705"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00705-9","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"16 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}